Check for updates

OPEN ACCESS

EDITED BY Jeroen Goossens, Radboud University Medical Centre, Netherlands

REVIEWED BY Greg D. Reynolds, The University of Tennessee, Knoxville, United States Audrey Morrow, University of California, San Francisco, United States

*CORRESPONDENCE Rebecca A. Lundwall ⊠ rebecca_lundwall@byu.edu

[†]These authors have contributed equally to this work

RECEIVED 14 June 2024 ACCEPTED 07 May 2025 PUBLISHED 30 May 2025

CITATION

Myres S, Christensen KE and Lundwall RA (2025) A systematic review and meta-analysis of the relationship between genes and reflexive attention. *Front. Neurosci.* 19:1449354. doi: 10.3389/fnins.2025.1449354

COPYRIGHT

© 2025 Myres, Christensen and Lundwall. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

A systematic review and meta-analysis of the relationship between genes and reflexive attention

Spencer Myres^{1†}, Katherine E. Christensen^{2†} and Rebecca A. Lundwall³*

¹Baylor College of Medicine, Houston, TX, United States, ²Pacific Graduate School of Psychology-Stanford PsyD Consortium, Palo Alto, CA, United States, ³Psychology Department, Brigham Young University, Provo, UT, United States

Defined as the semi-autonomous orientation to either a moving or rapidly appearing stimulus, reflexive attention (RA) is a crucial process for humans. While there are multiple outcomes used to assess RA, their relationships have not been tested. Disruptions in RA often relate to neurodevelopmental disorders, such as attention-deficit/hyperactivity disorder or autism spectrum disorder, so RA might be moderated by age. Additionally, the current academic consensus is that multiple genes influence RA, but this has not been assessed in a meta-analysis. A better understanding of RA using previously collected data will allow us to improve the design of future research studies.

Methods: In accordance with PRISMA, we conducted a broad search for potentially relevant articles pertaining to genes associated with RA. Selected studies included those (1) published in English, (2) involving human participants, and (3) referencing specific genetic markers in association with a measure of RA. For subgroup comparisons, we analyzed 14 studies assessing children and 23 assessing adults. We also compared 18 dopamine-related to 19 non-dopamine related studies.

Results: The main analysis produced a non-significant overall effect size; however, our most interesting finding was that results varied by age group. We explore this as well as difference by outcome type and the relation of the gene studied to dopamine.

Conclusion: Our findings vary by age group. However, due to heterogeneity we recommend more studies to answer some questions about a broader range of neurotransmitters, to include younger age groups, and to clarify difference by outcome type. We discuss issues of relevance to researchers to guide future meta-analyses.

Systematic review registration: Prospero: International prospective register of systematic reviews. Available from: https://www.crd.york.ac.uk/PROSPERO/ view/CRD42018090220.

KEYWORDS

meta-analysis, genetic influence, reflexive attention, development, children and adults, neurotransmitters

Introduction

Reflexive attention¹ (RA) is a process that has substantial implications for the cognitive, social, and emotional well-being of humans (Bagherzadeh-Azbari et al., 2023; Lundwall and Rasmussen, 2016; Pozuelos et al., 2014). It allows individuals to attend to potential dangers, obtain food within their environments, and even successfully interact and have relationships with others (Bagherzadeh-Azbari et al., 2023; Feng and Zhang, 2014; Phelps et al., 2006). Research suggests that children can demonstrate relative differences in RA development early on in life (Dannemiller, 2004; Holmboe et al., 2010; Jones and Kiln, 2013), variations of which impact neurodevelopmental disorders, such as attention-deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD).

In contrast to sustained attention (i.e., when an individual effortfully focuses on a stimulus for an extended period of time), RA occurs automatically as an individual orients their focus to the sudden appearance or movement of a stimulus (Richards and Hunter, 2002; Sechenov, 1863/1965; Smith and Chatterjee, 2008). Thus far, several genetic association studies have been completed with the aim to better understand the biological underpinnings of RA (Beane and Marrocco, 2004; Bobb et al., 2005; Lundwall et al., 2012; McCauley et al., 2004). These studies found, for example, that genetic markers associated with acetylcholine, dopamine, norepinephrine, and serotonin are associated with RA. However, reviews of these genetic studies, including meta-analyses, are much rarer.

Given that disorders involving attentional difficulties have been associated with a variety of genes and neurotransmitters (Bobb et al., 2005; Lundwall et al., 2017; McCauley et al., 2004) and that the variety of evidence has not previously been combined in a meta-analysis, we judged that the pooling of data may allow for a clearer estimate of neurotransmitter influence on RA.

Our study screened genetic studies of RA using strict criteria for inclusion in our meta-analysis. In addition to determining genetic influence by outcome type, we associate the genes with neurotransmitters to compare dopamine-related to non-dopaminerelated effects. Similarly, our interest in development from infancy to adulthood drove planned group analyses that would compare child to adult age groups.

Reflexive attention tasks

AUD Cz, target amplitude

Even-related potential (ERP) studies provide a reliable and sensitive method to investigate cognitive processes such as novelty detection, attentional allocation, and target discrimination (Gallinat et al., 2003). In the auditory modality, a number of ERP components (e.g., N1, P1) have been associated with the different stages of novelty processing. A common feature of these ERP components is that they are elicited even when sound is irrelevant for the subject's task (Birkas et al., 2006). Readings at the central electrode (Cz) in an auditory ERP study refer to the auditory target amplitude. Novelty processing reveals stages of sensory detection and attention reorientation (Birkas et al., 2006). Differences in ERP amplitudes generally offer insights into genotype-dependent variations in cognitive processing, although not necessarily into early attentional processing (Anokhin et al., 2001; Tye et al., 2011). This suggestions the possible heritable nature of reflexive attention (Gallinat et al., 2003; Reinvang et al., 2005). These measures are crucial for understanding the neural dynamics of sensory and attentional systems.

Benefit

The cued-orienting task (Posner, 1980) involves precues and targets flashing briefly on a computer display. It is taken as evidence that attention was captured by a precue if subjects were faster at responding to a subsequent target even though the stimuli presentation is too brief to depend on eye movement. Depending on the specific variation of the task, the precues can be valid (indicate where the target will subsequently appear), invalid (indicate the contralateral side from where the target ultimately appears), or neutral (does not provide location information). See Bellgrove et al. (2009) for a variation on this task. Benefits represent the tendency for participants to respond with shorter latencies (response times; RTs) when responding to validly cued targets than to targets following neutral precues. Benefits are calculated as neutral RT–valid RT.


Cost

A cost occurs when the participant is slower at responding to a target following an invalid cue than they are, on average, to a neutral cue. Costs usually follow invalid cues that suggest the target will appear on the side opposite where it subsequently appears. It is calculated as invalid RT – neutral RT. See Figure 1 for an illustration.

Flanker

The flanker task, originally introduced by Eriksen and Eriksen (1974), is a cognitive paradigm used to study visual attention and interference processing. In the version used most often in the studies included in the meta-analysis (Eriksen and Schultz, 1979), participants are required to respond to a central target (e.g., a letter or arrow) that has flanking distractors on either side. These distractors can be congruent (pointing in the same direction as the target; e.g., >>>> > or <<<<<) or incongruent (pointing in the opposite direction of the target; e.g., <<> < >). The congruency influences RT and accuracy, with faster and more accurate responses observed in congruent trials compared to incongruent ones. The task effectively measures the ability to suppress irrelevant information since incongruent distractors interfere with target processing, slowing RT and increasing error rates. Variations of the flanker task include noise conditions, neutral distractors, and blocked trial designs, further exploring the dynamics of attentional allocation and response

¹ Note that RA has sometimes been called "orienting" or "selective attention" in the literature; however, these terms also refer to voluntary orienting and selection. While we examined studies referring to orienting and selective attention to determine if they included examination of RA, RA is our preferred term.



competition. Scores represent the difference between response times when all flanking cues point in the opposite direction of a central cue versus when all cues point in the same direction. Thus, it is typically calculated as incongruent RT-congruent RT.

Gap effect

In the gap-no-gap task, there are two conditions that each involve shifting attention from a central stimulus to a peripheral target (Chernenok et al., 2019; Owen, 2015; Ross-Sheehy et al., 2015). The "gap" condition involves a central fixation stimulus that disappears before a peripheral target appears, creating a temporal gap. In the "overlap" condition, the fixation stimulus remains visible alongside the peripheral target, causing visual competition. The "gap effect" refers to the increased latency (via saccades) observed in the overlap condition compared to the gap condition, reflecting the recruitment of cortical and subcortical processes required for disengaging attention from the central stimulus. The gap–overlap task is a cognitive paradigm used to study attention-shifting mechanisms. The gap is thought to aid the disengagement of attention relative to a trial without a gap (Ross-Sheehy et al., 2015). The RT score is calculated as overlap RT–gap RT.

Valid orienting

One way to calculate scores is simply to time the latency of a look toward a valid cue. This is different from a Posner paradigm benefit because the latter subtracts RT to neutral cues. Thus, the valid orienting outcome is not adjusted for an individual's base RT in the same way that a benefit is.

Validity effect

Sometimes calculated when using a Posner paradigm, the validity effect is the difference in RT between validly and invalidly cued trials. Thus, it is calculated as invalid RT-valid RT. The task is usually a peripherally cued variation of the Posner paradigm, but benefits and costs are not necessarily provided (Schneider et al., 2015).

Neurotransmitter influence on reflexive attention

Some researchers have suggested that differences in attentional development are influenced by multiple genes (Beane and Marrocco, 2004; Bobb et al., 2005; McCauley et al., 2004; Saez et al., 2014), implying that individuals with attentional difficulties may carry alleles that affect their performance on attention-related tasks. If this is the case, neurotransmitters may have significant bearing on RA since they often prove the relevant pathway for the influence of genes on behavior (Beane and Marrocco, 2004; Saez et al., 2014).

Research has linked the influences of specific genes and neurotransmitters to the development of RA among infants and children; however, the findings are often mixed. For example, several researchers discuss genes, including *CHRNA4*, *COMT*, *MAOA*, and *SLC6A3* (Bellgrove et al., 2007; Markant et al., 2014; Quan et al., 2017; Zhang et al., 2011), which are associated with cholinergic,

dopaminergic, noradrenergic, and serotonergic (and, indirectly, with glutaminergic) neurotransmitters. In addition, Bellgrove et al. (2007) found that two variable number tandem repeats (VNTRs) were associated with the *SLC6A3* gene among typically developing children performing an RA task while Markant et al. (2014) showed that variations in the *COMT* gene, which influences dopamine in the brain, may contribute to individual differences in reflexive orienting during childhood.

These findings suggest that genes and neurotransmitters influence the development of RA in infancy and early childhood; however, no study to date has comprehensively assessed the relative importance of candidate genes, represented in various neurotransmitters, have on RA. Thus, a systematic review and meta-analysis is a key step to understanding the implications of genetic influence on difficulties with RA.

Reflexive attention across age groups

Research suggests that children can demonstrate deficits in RA development early on in life (Dannemiller, 2004; Holmboe et al., 2010; Jones and Kiln, 2013). These differences may sometimes involve the development of various neurodevelopmental disorders, such as ADHD or ASD. The development of RA appears within the first year of life (Harman et al., 1994; Quan et al., 2017; Ross-Sheehy et al., 2015; Rothbart et al., 2011) and is likely influenced by a variety of genes (Bellgrove et al., 2007; Markant et al., 2014; Zhang et al., 2011).

Several researchers indicate that the RA characteristics of children of six years and older do not differ much from those of adults (Brodeur and Enns, 1997; Plude et al., 1994; Waszak et al., 2010). Most development of RA may occur in infancy when looking durations tend to decrease with age (Colaizzi et al., 2014; Courage et al., 2006) and covert spatial orienting develops (Richards, 2005). Some evidence suggests that there are changes in RA such that younger children or more likely to experience costs following valid cues (Lundwall et al., 2018; although see Enns, 1990 and Waszak et al., 2010 for alternate findings). In addition, children become faster at locating a peripheral target in a field of distractors between 7 and 11 years old (Dye and Bavelier, 2010). However, there appear to be minimal differences in peripheral cueing between 7 and 73 years old (Brodeur and Enns, 1997).

Methods

Our aim for this meta-analysis was to include all candidate gene association studies with humans that test any specific genetic markers for association with RA. We based this on advice from several sources to ensure quality and accuracy of data (Boccia et al., 2010; Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, 2011; Gwinn et al., 2014; Minelli et al., 2009; Thompson et al., 2011) and conducted it in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework. PRISMA consists of both evidence-based guidelines for and transparency of reporting in meta-analyses. This study was pre-registered on 5 December 2017, at Prospero: International prospective register of systematic reviews. Available from: https://www.crd.york.ac.uk/PROSPERO/view/ CRD42018090220 and modified on 12 March 2018.

Search strategy

First, we surveyed core attention literature discussing the terminology for different tasks measuring RA. We also documented the years covered and how searches functioned within a given database (e.g., if we could use phrases in quotation marks in combination with a Boolean/Lucene search and if we could use parentheses for nesting terms).

Pilot testing on inclusion procedures occurred during Fall and Winter 2017–2018. To avoid any selection bias (Boccia et al., 2010; Eicher and Gruen, 2015), we conducted a broad, comprehensive literature search for potentially relevant articles pertaining to genes and RA. Our strategy consisted of searching each of the databases to determine the best search terms to yield the greatest number of relevant studies (see selection criteria below). However, we eventually searched simultaneously those databases that had the same search functionality (e.g., Boolean terms, nesting).


Eventually, we found that the following databases adequately identified relevant literature while avoiding unnecessary duplicate hits: Academic OneFile (Gale); APA PsycInfo; Academic Search Ultimate; Biomedical Reference Collection: Basic; CINAHL; ERIC; MEDLINE; Psychology and Behavioral Sciences Collection; Elsevier ScienceDirect; Elsevier Scopus; Embase (Medline hits removed); ProQuest (Dissertations & Theses); PubMed; Web of Science; and CDC-Authored Genomics and Precision Health Publications Database. Searches were not restricted by date of publication. We used the following search terms: genetic AND [("orienting" AND "attention") OR "reflexive attention" OR "exogenous attention" OR "peripheral attention" OR "selective attention"]. We examined each title and abstract and, if the article was apparently relevant, the full text with the assumption of inclusion until inclusion criteria were violated (see subsection "Search Strategy"). We also searched preprint repositories to avoid contributing to publication bias (see section "Publication Bias"). In bioRxiv, which also searches medRxiv and PsyArXiv repositories, we altered our search strategy because (a) nesting was not supported, (b) the same Boolean operator had to be used between each search term, and (c) Boolean terms could not be used with phrase search. Instead, we searched for titles and abstracts in these databases using two terms at a time. No additional useful hits were obtained from these repositories when searching the full texts.

We updated our search in April 2024, prior to article submission. In all searches, at least two team members confirmed exclusion of a study. For included articles, we also searched reference lists until saturation. For an illustration of our selection process, see Figure 2.

Selection criteria

We included studies if they were published in English², involved human participants, and referenced specific genetic markers in association with a measure of RA. Candidate gene association studies

² This was because we had no colleague willing and able to search for, comprehend, and extract effect sizes from non-English languages.



and genetic disorder association studies were included if they referenced RA performance between genetic groups or conditions. While genomewide associations are sometimes preferred (Mammen and Arcoleo, 2019), we could not include these studies since they only reported significant genes and could lead to issues with selective reporting.

Article reviewers worked independently to screen the titles and abstracts of all articles discovered using our search strategy. Studies included by either of the two reviewers were retrieved for full-text screening. Independent reviewers screened the full-text version of articles. If they could not reach consensus in determining whether the article was relevant to the current analysis, a third reviewer resolved the discrepancy. See Table 1 for exclusion data.

Data extraction

Before data extraction, we developed a standardized form to enter study characteristics, including group sample sizes, type of RA measure, means and standard deviation, direction of effect, and specific genetic markers in the analyses. See Table 2 for a list of articles included.

Genetic markers

After selecting the studies for final inclusion in the meta-analysis, we employed the following rules to help avoid problems with the

TABLE 1 Full-text articles evaluated but excluded from the meta-analysis.

Reason	Ν
Did not have the information we need	20
Full text no longer available	1
No attention task	60
No specific genetic marker	241
Not an empirical study	72
Not on attention	2
Not on humans	66
Only outcome of its type	3
Retracted	1
Wrong type of attention	294

non-independence of samples. We also checked for the use of duplicate samples across multiple papers since this would result in non-independence of data. However, none of the studies in our sample for meta-analysis included words or phrases that led us to believe the same data had been published more than once.

• If a single study had two outcomes for the same marker, we selected the more common of the two outcomes for inclusion to ensure at least two studies per outcome type.

TABLE 2 Articles included in the meta-analysis.

Study name	Overall N	Mean age (SD) range	Ethnicities	Genetic marker
Anguera et al. (2016)	111	10.4 (2.3) yrs	NR	16p11.2 DS
Bellgrove et al. (2007)	51	13.7 (2.1) 9–16 yrs	NR	SLC6A3
Bellgrove et al. (2009)	115	13.5 (1.9) yrs	NR	SLC6A3
Birkas et al. (2006)	57	6-7 yrs ³	NR	DRD4
Bish et al. (2007)	30	9.5 (2.2) 7–14 yrs	NR	22q11.2
Chernenok et al. (2019)	58	39.6 (19.4) mos	NR	FMR1
Cornish et al. (2008)	17	27 (NR) 3–55 mos	NR	FMR1
Couette et al. (2008)	28	46.5 (NR) 34–59 mos	NR	HTT
Espeseth et al. (2007)	42	62.2 (8.4) 48–75 yrs	NR	CHRNA4
Fan et al. (2003)	183	27.2 (5.7) yrs	NR	DRD4
Gallinat et al. (2003)	219	39.4 (8.3) yrs	100% Caucasian	COMT
Gallinat et al. (2007)	281	40.8 (0.19) yrs	NR	GRIN3A (aka NR3A)
Gao et al. (2018)	83	69.9 (0.29) 50-80 yrs	100% Asian	APOE
Greenwood et al. (2005)	177	59.4 (0.29) 41-85 yrs	NR	APOE
Lundwall et al. (2012)	161	25.32 (NR) 18-61 yrs	20% Asian; 5% Black; 61% White (15% Hispanic)	COMT
Lundwall et al. (2017)	201	13.0 (1.7) 9–16 yrs	100% Caucasian	COMT
Mannarelli et al. (2018)	20	26.0 (1.8) yrs	NR	22q11.2
Marco-Pallarés et al. (2010)	45	22.2 (NR) 18-35 yrs	NR	COMT
Markant et al. (2014)	88	7 (NR) 6.7–7.26 mos	6% Asian; 1% Black; 93% White	COMT
Maurage et al. (2017)	152	49.4 (3.7) yrs	NR	HTT
Newman et al. (2014)	518	21.6 (0.1) yrs	100% Caucasian	SLC6A3
O'Donoghue et al. (2014)	97	41.2 (12.0) 18-60 yrs	100% Caucasian	ZNF804A
Ortega-Mora et al. (2021)	127	23 (0.8), 20-30 yrs	NR	CNR1
Owen (2015)	124	18.0 (NR) 3.2-67.1 mos	NR	FMR1
Parasuraman et al. (2005)	89	35.2 (2.5) yrs	NR	CHRNA4
Quan et al. (2017)	276	183.4 (4.9) 174-194 days	100% Asian	COMT
Quintero et al. (2014)	129	10.5 (2.3) 7–15 yrs	NR	22q11.2
Reuter et al. (2007)	100	22.6 (4.7) yrs	100% Caucasian	COMT
Rose et al. (2019)	62	7.3 (3.1) 2–12 yrs	NR	MECP2
Schneider et al. (2015)	157	21 yrs. (median)	NR	CHRNA4
Schulz et al. (2012)	324	23.9 (2.7) 17-31 yrs	100% White	GRIN2B
Simon et al. (2005)	27	10 (2.7) 7–15.6 yrs	NR	22q11.2
Sobin et al. (2004)	69	7.9 (1.8) 5–14.1 yrs	NR	22q11.2
Thimm et al. (2010)	80	23.2 (2.9) 18-55 yrs	100% White	DTNBP1
Thimm et al. (2011)	46	23.3 (2.8) 18–55 yrs	NR	CACNA1C
Tsai et al. (1995)	65	[No mean provided]	NR	HTT
Zareyan et al. (2021)	156	24.2 (3.0) 20–35 yrs	26% Asian; 74% White	COMT

NR, not reported.

• If two or more genetic markers were tested in the same sample, we selected the non-dopamine related genetic marker. If there were multiple non-dopamine markers, then we selected the most common marker. If two single nucleotide polymorphisms (SNPs) from the same genetic marker were in the study, we included the more commonly studied SNP. In our final dataset, we included the following genetic markers: 16p11.2, 22q11.2, APOE, CACNA1C, CHRNA4, CNR1, COMT, DRD4, DTNBP1, FMR1, GRIN2B, GRIN3A, HTT, MECP2, SLC6A3, and ZNF804A. These are related to the neurotransmitters acetylcholine dopamine, epinephrine, norepinephrine, GABA, glutamate, and serotonin and to neurotransmitter modulation generally. Due to the greater number of studies involving dopamine generally, we classified the

studies in the meta-analysis into dopamine-related and non-dopamine related studies. We judged that finer tuned analysis was unwise given our sample size. Here we describe the biological mechanisms by which these genetic markers are proposed to have an influence on RA.

16p11.2

Deletions in this region of chromosome 16 are associated with a pattern of developmental delays, learning disabilities, and intellectual and attention-related conditions such as ASD (Anguera et al., 2016; Hanson et al., 2010; Kumar et al., 2009; Portmann et al., 2014; Weiss et al., 2008) and ADHD (Chung et al., 2021; Männik et al., 2015; Shiow et al., 2009).

22q11.2

The 22q11.2 locus contains 46 protein coding genes along with other pseudogenes and non-coding areas (Guna et al., 2015). Loss of the 22q11.2 locus has been linked to less cortical gyration. Psychiatric disorders related to attention such as schizophrenia, ASD, ADHD, and generalized anxiety disorder have all been shown to have higher prevalence in those with the 22q11.2 deletion (Schneider et al., 2014). Individuals with 22q11.2 deletion syndrome also seem to have difficulties with RA (Schneider et al., 2014; Simon et al., 2005).

APOE

The ε 4 haplotype of the *APOE* gene reduces acetylcholine receptor number and possibly diminishes the synthesis of acetylcholine via impaired regulation of phospholipid and/or fatty acid transport (Parasuraman et al., 2002; Poirier, 1996). Middle-aged, non-dementia carriers of ε 4 show difficulties with RA tasks (Greenwood et al., 2005).

CACNA1C

The *CACNA1C* gene encodes a calcium channel called the CaV1.2 channel. Calcium channels allow selective permeability to calcium ions and thus participate in creating action potentials across cell membranes (Zhang et al., 2023). In the brain, *CACNA1C* affects synaptic plasticity, learning, and memory. Ouyang et al. (2023) describe the connection between *CACNA1C*, schizophrenia, and attention (Meller et al., 2019; Thimm et al., 2011).

CHRNA4

This gene encodes a nicotinic acetylcholine receptor that can bind acetylcholine and open an ion-conducting channel across the plasma membrane. The protein can interact with either nAChR beta-2 or nAChR beta-4 (subunits of nicotinic acetylcholine receptors) to form a functional receptor (Winterer et al., 2007). Polymorphisms in this gene are associated with cognitive functions, including attention (Wallis et al., 2009).

CNR1

The *CNR1* gene encodes a cannabinoid receptor (CB1) that is expressed in the central and peripheral nervous systems. The receptor helps regulate working memory and attention (Papassotiropoulos and de Quervain, 2011; Ruiz-Contreras et al., 2017; Ruiz-Contreras et al., 2014; Stadelmann et al., 2011).

COMT

The G allele at rs4680 (an SNP) produces valine, which is more active in catabolizing—and thus reducing the availability

DRD4

Risk alleles on *DRD4* lead to fewer dopamine receptors via reduced transcription. There is an association between *DRD4* and ADHD (Lowe et al., 2004), and the 7-repeat allele has been associated with RT slopes in RA (Lundwall and Dannemiller, 2015). The *DRD4* receptor has been identified as a potential target for attention-improving medications (Ferré et al., 2022).

DTNBP1

Also known as the dystrobrevin-binding protein 1, *DTNBP1* acts by participating in neurotransmitter release, including glutamate. The disruption of neurotransmitter release can result in schizophrenia (Wang et al., 2017). Polymorphisms of *DTNBP1* have been hypothesized to reduce neural activity in prefrontal, temporal, and parietal regions of the brain (Thimm et al., 2010), affecting several cognitive processes, including attention.

FMR1

This gene causes fragile X syndrome (Chernenok et al., 2019), which is the most common inherited form of intellectual disability (Hunter et al., 2014; Tassone et al., 2012). Fragile X syndrome occurs when there is an expansion of the CGG trinucleotide within the *FMR1* gene. Such an expansion turns off the *FMR1* genes so that little of the normally resulting protein is produced (Verkerk et al., 1991) and attention is influenced (Cornish et al., 2008; D'Elia et al., 2022; Hunter et al., 2014; Meller et al., 2019; Van der Molen et al., 2012).

GRIN2B

This gene encodes a protein found in neurons during prenatal development (Shah et al., 2022). This protein (GluN2B) is essential for creating N-methyl-D-aspartate receptors involved in normal brain development, synaptic plasticity, learning, memory (Ciabarra et al., 1995; Sucher et al., 1995), and attention (Park et al., 2013; Schulz et al., 2012).

GRIN3A

Formerly known as *NR3A*, this gene is also involved with N-methyl-D-aspartate receptors. Its involvement in brain development is implied by gene expression peaking in early postnatal life (Das et al., 1998). It is also involved in schizophrenia, which has attentional aspects (Takata et al., 2013).

HTT

HTT produces the huntingtin protein, implicated in Huntington's disease. The protein is key in nerve cell signaling, axonal transport, and apoptosis (Nasir et al., 1995; Zhang et al., 2008). *HTT* is essential for normal prenatal brain development and healthy cognition, including attention (Ferré et al., 2022; Linderkamp and Linderkamp-Skoruppa, 2020).

MECP2

This gene regulates gene activity by modifying chromatin (Dunican et al., 2007) and thus silencing other genes to help maintain

cellular balance (Luikenhuis et al., 2004). Relatedly, *MECP2* is a calcium-dependent transcriptional repressor that alters brain development in ASD (Hawks and Constantino, 2020; Qiu and Cheng, 2010) and related conditions such as Rhett's syndrome and ADHD (Rose et al., 2019; Yenkoyan et al., 2017).

SLC6A3

SLC6A3 controls the number of dopamine transporters, resulting in less dopamine in the synapse and terminating the dopaminergic signal (Giros et al., 1992; Rommelse, 2008). Less dopamine has been associated with greater RA cueing costs for targets in the left hemifield (Bellgrove et al., 2007).

ZNF804A

The zinc finger protein 804A gene is expressed throughout the brain during development. Involved in dendritic morphology and synaptic development (Chen et al., 2015; Dong et al., 2021), it has also been studied in relation to attention (Nicodemus et al., 2014).

Analytic methods

We used Comprehensive Meta Analysis (CMA) software version 4.0 (Borenstein et al., 2022) to analyze our data, using means, standard deviations (*SDs*), sample size, and group membership (e.g., low-versus high-risk) to calculate overall effect size and related statistics. The genetic markers included in the meta-analysis are listed in Table 3. Twenty markers had their means and standard errors estimated from figures and then converted to SDs. We ran comparison analyses for age (child or adult) and neurotransmitter group (dopamine-related or not).

Results

Description of studies

In the final analysis, 37 studies were included. Data was from 3,228 participants (M age = 23.28; age range = 6 months to 70 years³). However, the effective sample size in a meta-analysis is the number of studies. We compared 14 studies assessing children (those with participants 0 to 18 years old) to 23 studies assessing adults. We also compared dopamine-related (n = 18) to non-dopamine-related (n = 19) studies. We did not restrict the meta-analysis to testing any specific gene because we wanted to examine the broader universe of studies to determine an effect size for the influence of genetic evidence on RA generally. See Table 3 for the classification of genetic markers as dopamine-related. There are more non-dopamine related markers in the data from studies on reflexive attention. To keep an approximately equal number of studies per group, we prioritized non-dopamine related genetic markers when selecting markers from already included studies that tested multiple markers. See Table 2.

TABLE 3 Genetic markers classified as dopamine-related.

Genetic marker	Source(s)
16p11.2	Portmann et al. (2014)
22q11.2	van Hooijdonk et al. (2022)
COMT	Chen et al. (2004)
DRD4	Nikolova et al. (2011)
DTNBP1	Andreou et al. (2011)
SLC6A3	Reith et al. (2022); Li et al. (2006b)

Determination of dopamine-relatedness relied on National Center for Biotechnology Information at https://www.ncbi.nlm.nih.gov.

Quality of studies included in the meta-analysis

To rate the quality of included studies, we used Q-Genie (Sohani et al., 2015), which is based on standards from genetic experts and journal editors (Freimer and Sabatti, 2003; Li and Meyre, 2013; Little et al., 2009; Nature Genetics Editorial Board, 2005). The developers of the Q-Genie measure (Sohani et al., 2015) used borderline groups regression (Wood et al., 2006) to benchmark the ranges of values that correspond to poor, moderate, and good genetic studies. Note that the questions on Q-Genie can be quite subjective. Sample questions are "Please rate the study on the technical classification of the exposure (i.e., the genetic variant)," "Please rate the study on the non-technical classification of the exposure (i.e., the genetic variant)," and "Please rate the study on description of planned analyses." Disciplines working with more subjective material are more likely to have lower values accepted as "good" inter-rater reliability.

The complexity of the ratings also influence what value qualifies as the benchmark of "good." Q-Genie has 11 items, each rated on a 7-point Likert scale. Gwet (2014, p. 171) notes that all benchmarking systems depend on the number of categories into which raters can place the item that is being rated (e.g., coefficients qualifying as good would be higher for two than for seven categories). Sohani and colleagues classify the Q-Genie measure as having "good" reliability (inter-rater reliability as 0.74) and good validity ($\rho = 0.30$, based on correlation between Q-Genie scores and impact factors). We used Q-Genie to judge each study by two reviewers and found that all values for studies were above the cut point for good quality studies.

Main meta-analysis results

We used a random effects model, which allows us to estimate an overall effect size and potentially generalize to a universe of comparable studies (Hedges and Vevea, 1998; Higgins et al., 2019). This model is also useful in predicting future results of similar studies (Higgins et al., 2009). The analysis produced a point estimate of the mean effect size, $\theta = 0.12$ (*SE* = 0.09; 95% *CI* -0.06 to 0.30). This indicates a non-significant overall effect for the influence of genes on RA (*Z* = 1.34, *p* = 0.18). See Figure 3 for the forest plot. Note that the prediction interval crosses zero (-0.97, 1.27). If we assume that the true effects are normally distributed, then we obtain the prediction interval that we can use to anticipate that the true effect of any single new study would fall in this interval (Borenstein, 2020; Higgins et al., 2003; Higgins and Thompson, 2002; IntHout et al., 2016). When the

³ Because not all studies provide age ranges, we describe the most commonly reported parameter, which was mean age.

prediction interval varies this way relative to the effect size estimate, the mean effect size becomes less interesting, and we focus instead on what influences the differences between studies. We do this in the section "Subgroup Analyses."

Assessment of heterogeneity

Our estimated τ^2 of 0.23 (*SD* = 0.48) represents the variance in the true effect size and is considered moderate. In addition, the I^2 of 0.80 indicates that 80% of the variance in observed effects reflects variance in true effects rather than sampling error. The Q-value, which tests the null hypothesis that the true effect size is the same in all these studies, is 180.04 (*df* = 36, *p* < 0.001). Using an alpha of 0.10, we reject the null hypothesis that the true effect size is the same in all included studies.

Publication bias

Publication bias occurs when studies with large effect sizes are more likely to be published, which can cause misleading overall estimates when performing a meta-analysis (Page et al., 2021; Vevea and Woods, 2005) because the data from studies that are wellconducted but non-significant should be included in estimating true effect sizes. To investigate the possibility of publication bias, we generated a funnel plot to assess left–right asymmetry and found asymmetry (see Figure 4). We also ran a Begg and Mazumdar's rank correlation test, which quantifies publication bias by looking for an inverse correlation between study size and effect size (Begg and Mazumdar, 1994; Boccia et al., 2010). We found no correlation (using continuity correction; Kendall's $\tau_{\rm b}$ correlation = 0.02, p = 0.86).

Sensitivity analyses

To better understand our results, we explored sensitivity to outlier studies, we also used one-study-removed methodology. Sensitivity analyses simply indicate how much results would change when studies are removed one at a time (Vevea and Woods, 2005). However, no matter which study we removed, the overall effect remained essentially the same (estimated effect sizes [θ s] ranged from 0.07 to 0.16, *p*-values ranged from 0.05 to 0.42). This suggests that the non-significance of our meta-analysis is not driven by the inclusion of any one study. Although there is no overall effect for genes on RA, we wanted to explore the possibility of effects dependent on the type of outcome used, age group (child or adult studies), and neurotransmitter groups (genes affecting dopamine or non-dopamine-related neurotransmitters).

Study name	Outcome			Statistics f			Std diff in means and 95% Cl		
		Std diff in means	Standard error	Variance	Lower limit	Upper limit	Z-Value	p-Value	
Anguera 2016	Flanker	-0.425	0.333	0.111	-1.077	0.227	-1.278	0.201	₭───┼ॼ───┼── ──│
Bellgrove 2007	cost	0.208	0.354	0.126	-0.486	0.903	0.588	0.557	
Bellgrove 2009	cost	1.045	0.239	0.057	0.577	1.513	4.377	0.000	
Birkas 2006	AUD Cz, target amplitude	-0.143	0.309	0.096	-0.749	0.464	-0.461	0.645	
Bish 2007	validity effect	0.437	0.369	0.137	-0.287	1.161	1.183	0.237	
Chernenok 2019	gap effect	-0.334	0.327	0.107	-0.975	0.307	-1.020	0.308	
Cornish 2007	valid orienting RT	0.498	0.407	0.165	-0.299	1.295	1.225	0.221	
Couette 2008	validity effect	0.894	0.396	0.157	0.117	1.671	2.256	0.024	
Espeseth 2007	AUD Cz, target amplitude	-0.382	0.418	0.175	-1.202	0.438	-0.913	0.361	└───
Fan 2003	Flanker	0.854	0.538	0.289	-0.201	1.908	1.587	0.112	
Gallinat 2003	AUD Cz, target amplitude	0.064	0.235	0.055	-0.397	0.525	0.272	0.786	
Gallinat 2003	AUD Cz, target amplitude	0.687	0.235	0.034	0.325	1.048	3.723	0.000	
Gao 2018	AUD Cz. target amplitude	-0.710	0.316	0.004	-1.329	-0.091	-2.247	0.025	
Greenwood 2005	validity effect	0.431	0.310	0.029	0.099	0.763	2.548	0.025	
Lundwall 2012	cost	-0.598	0.109	0.029	-1.176	-0.020	-2.027	0.043	
Lundwall 2012	cost	-0.598	0.295	0.087	-0.496	-0.020	-2.027	0.043	
Lundwall 2017 Vannarelli 2018	AUD Cz, target amplitude	-0.028	0.239	0.057	-0.496	0.440	-0.117	0.907	
Varinarelli 2018 Varco-Pallarés 2010	AUD Cz, target amplitude	-1.294		0.200	-0.784	-0.651	-3.945	0.000	
Marco-Pailares 2010 Markant 2014		-1.294 0.197	0.328 0.256		-1.936	-0.698	-3.945		
	benefit			0.065				0.441	
Maurage 2017	benefit	-0.300	0.318	0.101	-0.923	0.323	-0.943	0.345	
New man 2014	validity effect	0.064	0.176	0.031	-0.282	0.409	0.361	0.718	
O'Donoghue 2014	AUD Cz, target amplitude	0.195	0.206	0.042	-0.209	0.599	0.948	0.343	
Ortega-Mbra 2021	benefit	0.123	0.217	0.047	-0.303	0.548	0.565	0.572	
Ow en 2015	gap effect	0.182	0.208	0.043	-0.225	0.589	0.877	0.380	
Parasuraman 2005	validity effect	-0.053	0.273	0.074	-0.587	0.482	-0.194	0.846	
Quan 2017	valid orienting RT	0.197	0.235	0.055	-0.263	0.657	0.839	0.402	
Quintero 2014	validity effect	0.178	0.237	0.056	-0.287	0.643	0.751	0.453	
Reuter 2007	benefit	-0.011	0.137	0.019	-0.279	0.258	-0.077	0.939	
Rose 2019	gap effect	0.017	0.254	0.065	-0.481	0.515	0.067	0.946	
Schneider 2015	validity effect	-1.429	0.242	0.059	-1.904	-0.953	-5.893	0.000	★
Schulz 2012	benefit	-0.001	0.111	0.012	-0.219	0.217	-0.011	0.991	│ │ ————— │
Simon 2005	validity effect	1.920	0.467	0.218	1.004	2.836	4.110	0.000	
Sobin 2004	benefit	-0.204	0.286	0.082	-0.764	0.356	-0.715	0.475	
Thimm2010	benefit	0.464	0.235	0.055	0.002	0.925	1.970	0.049	
Thimm 2011	benefit	2.934	0.471	0.221	2.012	3.857	6.237	0.000	
Tsai 1995	validity effect	0.601	0.292	0.085	0.028	1.173	2.056	0.040	
Zareyan 2021	Flanker	-0.237	0.171	0.029	-0.572	0.097	-1.391	0.164	
Pooled		0.124	0.093	0.009	-0.058	0.305	1.335	0.182	
Prediction Interval		0.124	0.000	0.000	-0.876	1.123			
		0.124			0.0.0	20			-1.00 -0.50 0.00 0.50
									-1.00 0.00 0.00
									Hiah Risk Low Risk
									High Risk Low Risk

FIGURE 3

Meta-analytic results and forest plot.

Subgroup analyses

Group comparisons were performed based on the interests of study authors. In addition to comparison by outcome type, we were interested in age (child or adult) and in the neurotransmitter dopamine, including genetic studies that point to the importance of dopamine in RA (Bellgrove et al., 2007; Bellgrove et al., 2008).

Outcome type

There were seven types of outcomes. Each have their own point estimates, prediction intervals, and heterogeneity statistics. This can be seen in the pooled results at the bottom of each outcome type in Figure 5. Here we review some interesting findings.

First, the significance of genetic studies in predicting RA did not vary by outcome type. The most significant outcome was valid RT with a θ = 0.27 (*SE* = 0.20, 95% *CI* = 0.13, 0.67) and a *p*-value of 0.04. It has a non-calculatable prediction interval, probably due to a low number of studies included (*n* = 2). Gap effect had a similar problem (*n* = 3 studies).


Second, associated heterogeneity analyses indicate that costs and validity effects have the highest between-study variance, $\tau^2 = 0.45$, SD = 0.67 and $\tau^2 = 0.48$, SDs = 0.69, respectively. The outcome types with low between-study variance was flanker congruency effect ($\tau^2 = 0.12$, SD = 0.34), excepting gap effect and valid RT which did not

have calculable between-study variance. We also obtained I^2 statistics (81–86% for the first three outcomes and 54% for flanker congruency effects), but note that they do not represent variance in the studies, but the proportion of variance in true effects relative to variance in observed effects.

Age group

For children, we obtained a point estimate of $\theta = 0.27$ (*SE* = 0.13, 95% *CI* = 0.02, 0.52). This is significant (*Z* = 2.09, p = 0.04) but has a wide prediction interval (-0.61, 1.15). Alternatively, for adults, we obtained a point estimate of $\theta = 0.03$ (*SE* = 0.12, 95% *CI* = -0.21, 0.28). This was not significant (*Z* = 0.27, p = 0.78) and also has a wide prediction interval. See Figure 6. The different effects on children and adults are intriguing and addressed in the Discussion section.

In addition, variances differed across age groups with adult studies showing more variance ($\tau^2 = 0.27$, SD = 0.52) than child studies ($\tau^2 = 0.15$, SD = 0.38). We also obtained I^2 heterogeneity statistics (84% for adult studies and 65% for child studies). These represent the proportion of variance in true effects relative to variance in observed effects. The prediction intervals for adults (-1.07 to 1.14) and children (-0.61, 1.15) both indicate that future studies are likely to have an effect size that would fall in this interval (Borenstein, 2020; Higgins et al., 2003; Higgins and Thompson, 2002; IntHout et al., 2016). So,



while the significant child studies are intriguing, there is not yet assurance that future studies would also be significant.

Dopamine-related genetic markers

Lastly, we were curious if genetic markers related to the availability of dopamine had a lower or higher effect than non-dopamine genetic markers. For non-dopamine related genetic markers, we obtained a point estimate of θ = 0.11 (SE = 0.12, 95% CI = -0.12, 0.33). This is not significant (Z = 0.93, p = 0.35) and has a prediction interval from -0.79, 1.00. For dopamine-related genetic markers, we obtained a point estimate of θ = 0.14 (SE = 0.15, 95% CI = -0.15, 0.44), which is similarly not significant (Z = 0.96, p = 0.34) and has a prediction interval (-1.10, 1.38). Figure 7 illustrates the results. As with age group, variances differed across age groups with dopamine-related studies showing more variance ($\tau^2 = 0.32$, SD = 0.56) than non-dopamine studies ($\tau^2 = 0.17$, SD = 0.41). I^2 heterogeneity statistics did not appear to vary substantially (85% for dopamine-related studies and 72% for non-dopamine-related studies). The prediction intervals for dopamine-related studies (-1.10 to 1.38) and non-dopaminerelated studies (-0.79, 1.00) both indicate that future studies are likely to have an effect size that would fall in this interval (Borenstein, 2020; Higgins et al., 2003; Higgins and Thompson, 2002; IntHout et al., 2016).

Discussion

Our study is the first to summarize the literature concerning possible genetic influence on RA. Although we did not find a significant overall effect for the influence of genes on RA, we explored subgroups which did show a significant differences. We address possible reasons for the whole-group non-significant difference in light of subgroup findings. This includes examining differences by outcome type and if moderators such as age and the influence of dopamine played a role in estimates of effect size. In total, we synthesized evidence from articles from 1994 to 2023 that studied RA in human participants and that analyzed the influence of at least one genetic marker.

Although the overall meta-analysis did not show a statistically significant effect size for a general genetic influence on RA, children did show a genetic effect on RA while adults did not. This difference is interesting in itself, and we discuss it in more depth below. As noted earlier, when results vary like this, the mean effect size of combined groups becomes less interesting, and we focus instead on what influences the differences between studies. Here, we examine the results by comparing genetic influence on RA depending on outcome type, age group, and the dopamine-relatedness of the gene (Godfrey et al., 2018; Lehmann et al., 2022; Li et al., 2006a; Little et al., 2012).

ALD C2, target amplitude Espes ALD C2, target amplitude Gallin ALD C2, target amplitude Gallin ALD C2, target amplitude Gallin ALD C2, target amplitude Gallin ALD C2, target amplitude Mann ALD C2, target amplitude Mann ALD C2, target amplitude Predi ALD C2, target amplitude Predi benefit Mature benefit Mature benefit Schul benefit Schul benefit Predi Schul benefit Predi Cost Bellgr Cost Lundy Cost Predi Ranker Angu	salidion Interval urigen 2014 urigen 2017 lega-Mora 2021 uter 2007 hulz 2012 bin 2004 imm 2010 oled salidion Interval ligrove 2009 Indvall 2012 ndvall 2012 ndvall 2017 oled salidion Interval guera 2016	AUD Cz, target amplitude AUD Cz, target amplitude benefit benefit benefit benefit benefit benefit benefit benefit benefit benefit benefit benefit benefit benefit	Std diff in means -0.143 -0.382 0.064 0.867 -0.110 0.113 -1.234 0.153 0.153 0.153 0.197 -0.300 0.123 0.011 -0.204 0.464 2.934 0.278 0.278 0.268 1.045 0.268 0.166 0.166	Standard error 0.309 0.418 0.325 0.184 0.326 0.426 0.227 0.256 0.318 0.217 0.137 0.111 0.286 0.217 0.138 0.318 0.354 0.354 0.235 0.239 0.239 0.363 0.364	Variance 0.096 0.175 0.055 0.034 0.100 0.200 0.108 0.042 0.051 0.065 0.101 0.047 0.012 0.055 0.221 0.055 0.221 0.055 0.221 0.057 0.087 0.057	Lower limit -0.749 -1.202 -0.397 -0.325 -0.764 -1.329 -0.209 -0.299 -0.299 -0.299 -0.299 -0.303 -0.303 -0.279 -0.219 -0.310 -0.517 -0.310 -0.517 -0.310 -0.517 -0.310 -0.517 -0.5	Upper limit 0.464 0.438 0.525 1.048 0.629 0.091 0.599 0.595 0.599 0.591 0.599 0.591 0.599 0.591 0.599 0.591 0.599 0.591 0.597 0.591 0.597	-0.461 -0.913 0.272 3.723 3.723 3.725 -2.247 0.252 -3.948 -0.676 0.771 -0.943 0.565 -0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027	P-Value 0.645 0.361 0.786 0.000 0.025 0.801 0.000 0.343 0.499 0.441 0.345 0.577 0.049 0.557 0.049 0.557 0.000 0.497						
ALD C: target amplitude Espes ALD C: target amplitude Galin ALD C: target amplitude Galin ALD C: target amplitude Galin ALD C: target amplitude Galin ALD C: target amplitude Mann ALD C: target amplitude Mann ALD C: target amplitude Mann ALD C: target amplitude Predi ALD C: target amplitude Predi Predi D: target amplitude Predi D: target amplitude Predi D	seseth 2007 Illinat 2003 Illinat 2007 Illinat 2007 Illinat 2007 Illinat 2007 Jonoghue 2018 Jonoghue 2014 Oled Oled 2014 Julia 2014 Julia 2017 Oled Jono Illigrove 2007 Illigrove 2009 Indvall 2012 Oled 2017 Oled Jolica Jona 2019 Oled 2019 Oled 2019 Oled 2019 Oled 2019 Oled 2019 Oled 2019 Oled 2019 Oled 2019 Oled 2019	ALD C2; target amplitude ALD C2; target amplitude benefit benefit benefit benefit benefit benefit benefit	-0.382 0.064 0.687 -0.710 0.113 -1.294 0.153 -0.153 -0.153 -0.153 -0.153 -0.153 -0.153 -0.153 -0.011 -0.204 0.204 0.204 0.208 0.208 0.208 -0.598 -0.598 -0.598 -0.598 -0.598	0.418 0.235 0.184 0.316 0.328 0.206 0.227 0.256 0.318 0.217 0.137 0.111 0.286 0.235 0.471 0.188 0.354 0.239 0.255 0.239	0.175 0.055 0.034 0.100 0.200 0.108 0.042 0.051 0.065 0.101 0.047 0.012 0.082 0.055 0.221 0.035 0.126 0.057 0.087	-1.202 -0.397 -0.397 -1.329 -0.764 -1.936 -0.209 -0.598 -1.640 -0.923 -0.303 -0.279 -0.219 -0.764 -0.022 2.012 -0.092 2.012 -0.0952 -0.486 0.577 -1.176 -0.496	0.438 0.525 1.048 0.091 0.990 0.651 0.599 0.291 1.333 0.698 0.323 0.548 0.258 0.323 0.548 0.258 0.257 0.366 0.925 3.857 0.366 1.507 0.903 1.513 -0.903 1.513	-0.913 0.272 3.723 3.723 -2.247 0.252 -3.948 -0.676 0.771 -0.943 0.565 -0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027	0.361 0.786 0.025 0.801 0.000 0.343 0.499 0.441 0.345 0.572 0.499 0.475 0.499 0.475 0.499 0.475 0.409 0.475 0.409 0.475						
ALD C2, target amplitude Gallin ALD C2, target amplitude Gallin ALD C2, target amplitude Gao 2 ALD C2, target amplitude Manc ALD C2, target amplitude Manc ALD C2, target amplitude Poole ALD C3, target amplitude Poole ALD C4, target amplitude Poole ALD C4, target amplitude Poole benefit Mature benefit Schul benefit Schul benefit Poole benefit P	Illinat 2003 Illinat 2007 io 2018 Illinat 2018 Innoaelli 2018 Innoaelli 2018 Innoaelli 2018 Innoaelli 2018 Innoaelli 2018 Intervat 2014 Intervat 2014 Inter 2007 Intervat 2012 Intervat 2010 Intervat Ilgrove 2007 Ilgrove 2007	ALD C2; target amplitude ALD C2; target amplitude benefit benefit benefit benefit benefit benefit benefit benefit benefit	0.064 0.687 0.710 0.113 -1.294 0.153 -0.153 -0.153 -0.153 -0.153 -0.153 -0.011 -0.001 -0.204 -0.278 0.2780 0.2780 0.2780 0.27800000000000000000000000000000000000	0.235 0.184 0.316 0.448 0.228 0.226 0.227 0.256 0.318 0.217 0.137 0.111 0.286 0.235 0.471 0.188 0.354 0.239 0.239 0.235	0.055 0.034 0.100 0.200 0.108 0.042 0.051 0.065 0.101 0.047 0.012 0.082 0.055 0.221 0.035 0.126 0.057 0.057 0.057	-0.397 0.325 -1.329 -0.764 -1.936 -0.209 -0.598 -1.640 -0.304 -0.923 -0.303 -0.279 -0.219 -0.219 -0.764 0.002 2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	0.525 1.048 -0.091 0.990 0.291 1.333 0.698 0.323 0.548 0.323 0.548 0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	0.272 3.723 -2.247 0.252 -3.945 0.948 -0.676 0.771 -0.948 -0.676 0.771 -0.9585 -0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -0.058	0.786 0.000 0.025 0.801 0.034 0.343 0.499 0.441 0.345 0.572 0.475 0.475 0.475 0.475 0.475 0.475 0.475 0.475 0.479				╷ _┷ ╺┿╽╼┝╽┙╢╼╶║		
ALD C2, target amplitude Galiir ALD C2, target amplitude Galiir ALD C2, target amplitude Mann ALD C2, target amplitude Macn ALD C2, target amplitude Macn ALD C2, target amplitude Predi benefit OTbor benefit Galiir Matri benefit Schul benefit Schul benefit Predi Cost Bellgr Cost Lundw Cost Predi Cost Predi Cost Predi Cost Predi Cost ALD C3 Flanker Angu	ullinat 2007 oo 2018 nmarellii 2018 nroc-Pailarés 2010 Jonoghue 2014 oled oled sidicion Interval urage 2017 urage 2017 urage 2017 uter 2007 huiz 2012 bin 2004 imm 2010 imm 2010 idiction Interval ligrove 2007 ligrove 2007 ligrove 2007 oled dold 2017 oled guera 2016	ALD C2; target amplitude ALD C2; target amplitude benefit benefit benefit benefit benefit benefit benefit	0.687 0.710 0.113 -1.294 0.195 -0.153 0.197 -0.300 0.123 -0.011 -0.001 -0.204 0.464 2.934 0.278 0.264 0.278 0.278 0.278 0.278 0.278 0.278 0.278 0.278 0.278 0.278 0.278 0.278 0.278 0.278 0.278 0.278 0.278 0.264 0.278 0.278 0.278 0.264 0.264 0.278 0.268 0.268 0.278 0.268 0.268 0.278 0.268 0.268 0.278 0.268 0.268 0.268 0.278 0.268 0.268 0.268 0.268 0.268 0.278 0.268 0.268 0.268 0.268 0.268 0.278 0.268 0.2	0.184 0.316 0.448 0.328 0.206 0.227 0.25 0.318 0.217 0.137 0.111 0.286 0.235 0.471 0.188 0.354 0.239 0.239 0.235	0.034 0.100 0.200 0.108 0.042 0.051 0.065 0.101 0.047 0.019 0.012 0.082 0.055 0.221 0.035 0.126 0.057 0.087	0.325 -1.329 -0.764 -1.936 -0.209 -0.598 -1.640 -0.304 -0.304 -0.304 -0.304 -0.303 -0.279 -0.219 -0.764 0.002 2.012 2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	1.048 -0.091 0.990 0.651 0.599 0.291 1.333 0.698 0.228 0.217 0.356 0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.903 1.513	3.723 -2.247 0.252 -3.945 -0.948 -0.676 0.771 -0.943 0.565 -0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.000 0.025 0.801 0.000 0.343 0.499 0.441 0.345 0.345 0.345 0.345 0.372 0.399 0.475 0.099 0.475 0.000 0.139 0.557 0.000 0.043 0.057				<u>,</u> , , , , , , , , , , , , , , , , , ,		
ALD C2, target amplitude Go 2, ALD C2, target amplitude Go 2, ALD C2, target amplitude Mann ALD C2, target amplitude Poole ALD C2, target amplitude Poole ALD C2, target amplitude Poole ALD C2, target amplitude Poole benefit Marka benefit Marka benefit Schul benefit Schul benefit Schul benefit Thirm benefit Predic Cost Bellgr Cost Bellgr Cost Hord Predic Cost Predic Cost Predic Cost Predic Cost Angue Flanker Angue	io 2018 immarelli 2018 immarelli 2018 immarelli 2018 oled addition Interval addition Interval addition Interval uter 2007 imm 2010 imm 2010 imm 2010 imm 2010 addition Interval Ilgrove 2007 Ilgrove 2009 ndwall 2012 oled addition Interval guera 2016	ALD C2; target amplitude ALD C2; target amplitude ALD C2; target amplitude ALD C2; target amplitude ALD C2; target amplitude benefit benefit benefit benefit benefit benefit benefit benefit benefit	-0.710 0.113 -1.294 0.195 0.153 0.197 -0.300 0.123 -0.011 -0.001 0.204 0.464 0.278 0.278 0.278 0.278 0.278 0.278 0.278 0.288 -0.0588 -0.05888 -0.0588 -0.0588	0.316 0.448 0.328 0.206 0.227 0.256 0.318 0.217 0.137 0.111 0.286 0.235 0.471 0.188 0.354 0.239 0.239 0.235	0.100 0.200 0.108 0.042 0.051 0.065 0.101 0.047 0.019 0.012 0.082 0.055 0.221 0.035 0.126 0.057 0.087	-1.329 -0.764 -1.936 -0.298 -1.640 -0.304 -0.923 -0.303 -0.279 -0.219 -0.764 0.002 2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	-0.091 0.990 -0.651 0.291 1.333 0.698 0.323 0.548 0.258 0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	-2.247 0.252 -3.945 0.948 0.6676 0.7771 -0.943 0.565 -0.077 -0.017 1.970 6.237 1.479 0.588 4.377 -2.027	0.025 0.801 0.000 0.343 0.499 0.441 0.345 0.572 0.039 0.991 0.475 0.049 0.045 0.045 0.000 0.139 0.557 0.000 0.043 0.907				╶╺╺╢┥┥┧╢╴╢┽		
ALD C2, target amplitude Mann ALD C2, target amplitude Mann ALD C2, target amplitude ODD ALD C2, target amplitude Poel benefit Mark benefit Mark benefit Otteg benefit Schul benefit Schul benefit Thirm benefit Pictor benefit Pictor benefit Pictor benefit Pictor benefit Pictor benefit Pictor benefit Pictor benefit Pictor benefit Pictor benefit Pictor Cost Beligr Cost Lundw Cost Pictor Cost	innarelli 2018 inco-Pallarks 2010 Donoghue 2014 oled oled siciaion Interval urera 2017 lega-Mora 2021 uter 2007 hulz 2012 bin 2004 imm 2010 imm 2010 oled siciaion Interval Ilgrove 2007 Ilgrove 2009 ndvall 2012 ndvall 2012 oled siciaion Interval siciaion Interval	ALD C2; target amplitude ALD C2; target amplitude ALD C2; target amplitude ALD C2; target amplitude benefit benefit benefit benefit benefit benefit benefit benefit	0.113 -1.294 0.195 -0.153 -0.153 -0.153 -0.153 -0.011 -0.204 -0.204 -0.204 -0.278 0.208 -0.278 0.208 -0.278 0.208 -0.598 -0.028 -0.028 -0.028	0.448 0.328 0.226 0.227 0.358 0.217 0.137 0.137 0.235 0.471 0.285 0.471 0.188 0.354 0.235 0.239 0.295 0.239	0.200 0.108 0.042 0.051 0.065 0.101 0.047 0.019 0.047 0.085 0.221 0.055 0.221 0.035 0.126 0.057 0.087	-0.764 -1.936 -0.209 -0.598 -1.640 -0.304 -0.923 -0.303 -0.279 -0.279 -0.764 0.002 2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	0.990 -0.651 0.599 0.291 1.333 0.698 0.323 0.548 0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	0.252 -3.945 0.948 -0.676 0.771 -0.943 0.565 -0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.801 0.000 0.343 0.499 0.441 0.345 0.572 0.931 0.475 0.049 0.000 0.000 0.139 0.557 0.000 0.043 0.907				₊ ┿ <u>╢</u> ┿╟ <u>┿</u> ╽ <u>┥</u> ╽╢		
ALD C2, target amplitude Marcz ALD C2, target amplitude ODor ALD C2, target amplitude ODor ALD C2, target amplitude Proofe ALD C2, target amplitude Proofe benefit Marka benefit Marka benefit Schul benefit Schul benefit Thirm benefit Prodie benefit Thirm benefit Prodie cost Beligg cost Lundword cost Prodie planker Zarey	rrco-Pallarés 2010 Jonoghue 2014 oled oled vient 2014 urage 2017 uter 2007 huiz 2012 bin 2004 bin 2004 bin 2010 limm 2010 limm 2011 oled diction Interval ligrove 2007 ligrove 2009 ndveil 2012 ndveil 2017 oled oled guera 2016	ALD C2; target amplitude AUD C2; target amplitude benefit benefit benefit benefit benefit benefit benefit benefit benefit cost cost cost cost cost cost	-1.294 0.195 -0.153 0.197 -0.300 0.123 -0.011 -0.204 0.464 2.934 0.278 0.278 0.278 0.278 0.208 1.045 -0.598 -0.028	0.328 0.206 0.227 0.256 0.217 0.137 0.111 0.285 0.471 0.188 0.354 0.239 0.239 0.235	0.108 0.042 0.051 0.065 0.101 0.047 0.012 0.082 0.055 0.221 0.035 0.126 0.057 0.057	-1.936 -0.209 -0.598 -1.640 -0.304 -0.923 -0.303 -0.279 -0.219 -0.764 0.002 2.012 -0.090 -0.952 -0.486 0.577 -1.176	-0.651 0.599 0.291 1.333 0.698 0.323 0.548 0.258 0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	-3.945 0.948 -0.676 0.771 -0.943 0.565 -0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.000 0.343 0.499 0.441 0.345 0.572 0.939 0.97 0.475 0.049 0.049 0.000 0.139 0.557 0.000 0.433 0.907				┥┑╿ ┙┝╹╹		
ALD C2, target amplitude Poole ALD C2, target amplitude Poole ALD C2, target amplitude Predic benefit Matrix benefit Matrix benefit Matrix benefit Ctarget benefit Reute benefit Schul benefit Thirm benefit Thirm benefit Predic cost Bellgr cost Lurdw cost Predic cost Predic cost Predic cost Predic Flanker Angue Flanker Zarey	Danoghue 2014 oled sidioin Interval sirkant 2014 uurage 2017 lega-Mora 2021 uter 2007 huiz 2012 bin 2004 imm 2010 oled sdiction Interval Ilgrove 2007 Ilgrove 2009 ndvali 2012 ndvali 2012 ndvali 2012 oled sdiction Interval sdiction Interval sdiction Interval sdiction Interval sdiction Interval sdiction Interval	ALD Cz, target amplitude benefit benefit benefit benefit benefit benefit benefit benefit cost cost cost cost cost	0.195 0.153 0.153 0.197 0.300 0.123 0.011 0.204 0.464 0.278 0.278 0.278 0.278 0.208 1.045 0.598 0.028	0.206 0.227 0.256 0.318 0.217 0.111 0.286 0.235 0.471 0.188 0.354 0.239 0.295 0.239	0.042 0.051 0.065 0.101 0.047 0.019 0.012 0.082 0.055 0.221 0.035 0.126 0.057 0.087	-0.209 -0.598 -1.640 -0.304 -0.923 -0.279 -0.219 -0.219 -0.764 0.002 2.012 -0.090 -0.952 -0.4557 -1.176 -0.496	0.599 0.291 1.333 0.698 0.323 0.548 0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 0.020 0.440	0.948 -0.676 0.771 -0.943 0.565 -0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.343 0.499 0.441 0.345 0.572 0.999 0.991 0.475 0.049 0.000 0.139 0.557 0.000 0.433 0.907				┿╽┿╽┿╽┷╽┙╿┿╴╽╽		
ALD C2, target amplitude Poole ALD C2, target amplitude Prodic benefit Marka benefit Otteg benefit Schul benefit Schul benefit Thirm benefit Thirm benefit Prodic cost Bellgr cost Bellgr cost Lundw cost Prodic cost Prodic cost Prodic	oled satidion Interval irrant 2014 Jurage 2017 lega-Mora 2021 uter 2007 hutz 2012 bin 2004 imm 2011 oled diction Interval Ilgrove 2007 Ilgrove 2009 ndvali 2012 ndvali 2012 ndvali 2017 oled diction Interval guera 2016	benefit benefit benefit benefit benefit benefit benefit benefit cost cost cost cost cost cost	-0.153 -0.153 -0.153 -0.300 -0.201 -0.204 -0.204 -0.208 -0.278 -0.278 -0.278 -0.278 -0.278 -0.268 -0.268 -0.028 -0.026 -0.166	0.227 0.256 0.318 0.217 0.137 0.111 0.286 0.235 0.471 0.188 0.354 0.299 0.295 0.239	0.051 0.065 0.101 0.047 0.019 0.012 0.082 0.055 0.221 0.035 0.25 0.25 0.035	-0.598 -1.640 -0.304 -0.923 -0.279 -0.279 -0.764 -0.090 -0.952 -0.480 0.577 -1.176	0.291 1.333 0.698 0.323 0.548 0.258 0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	-0.676 0.771 -0.943 0.565 -0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.499 0.441 0.345 0.572 0.939 0.991 0.475 0.049 0.000 0.139 0.557 0.000 0.043 0.907				┿╽┿╽ _{┿╽┧} ║╶╿┝╸╽		
ALD Cz, target amplitude Prediable benefit Marka benefit Marka benefit Marka benefit Reute benefit Schin benefit Schin benefit Thirm benefit Thirm benefit Thirm benefit Poole benefit Bellgr cost Bellgr cost Poole cost Poole <	salidion Interval urigen 2014 urigen 2017 lega-Mora 2021 uter 2007 hulz 2012 bin 2004 imm 2010 imm 2010 oled salidion Interval Ilgrove 2009 Ilgrove 2009 ndvall 2012 ndvall 2012 ndvall 2017 oled salidion Interval guera 2016	benefit benefit benefit benefit benefit benefit benefit cost cost cost cost cost	-0.153 0.197 -0.300 0.123 -0.011 -0.001 -0.204 0.464 2.934 0.278 0.278 0.278 0.208 1.045 -0.598 -0.028 0.166	0.256 0.318 0.217 0.137 0.111 0.286 0.235 0.471 0.188 0.354 0.239 0.295 0.239	0.065 0.101 0.047 0.019 0.012 0.082 0.055 0.221 0.035 0.126 0.057 0.087	-1.640 -0.304 -0.923 -0.303 -0.279 -0.219 -0.764 0.002 2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	1.333 0.698 0.323 0.548 0.258 0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	0.771 -0.943 0.565 -0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.441 0.345 0.572 0.939 0.991 0.475 0.049 0.000 0.139 0.557 0.000 0.043 0.907						
benefit Marka benefit Marka benefit Orteg benefit Schul benefit Schul benefit Schul benefit Thimm benefit Pradit cost Belig cost Belig cost Lundw cost Lundw cost Procie Cost Procie Cost Procie Cost Procie	whant 2014 surage 2017 lege-Mora 2021 uter 2007 huiz 2012 bin 2004 imm 2010 imm 2010 imm 2011 oled diction Interval Ilgrove 2007 Ilgrove 2009 ndvali 2012 ndvali 2017 oled diction Interval guera 2016	benefit benefit benefit benefit benefit benefit benefit cost cost cost cost cost	0.197 -0.300 0.123 -0.011 -0.204 0.464 2.934 0.278 0.278 0.278 0.278 0.208 1.045 -0.598 -0.028 0.166	0.318 0.217 0.137 0.111 0.286 0.235 0.471 0.188 0.354 0.239 0.295 0.239	0.101 0.047 0.019 0.022 0.082 0.055 0.221 0.035 0.126 0.057 0.087 0.057	-0.304 -0.923 -0.303 -0.279 -0.219 -0.764 0.002 2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	0.698 0.323 0.548 0.258 0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	-0.943 0.565 -0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.345 0.572 0.939 0.991 0.475 0.049 0.000 0.139 0.557 0.000 0.043 0.907				┿ <u>┥</u> ┥ <u>╷</u> ┥┥ <u>┥</u>		
benefit Maure benefit Ortegy benefit Reute benefit Schul benefit Thimm benefit Thimm benefit Poole benefit Produ benefit Produ cost Bellgr cost Bellgr cost Bellgr cost Bellgr cost Poole cost Predu Flanker Angue Flanker Zarey	ыладе 2017 еда-Мога 2021 uter 2007 hulz 2012 bin 2004 imm 2010 oled adiction Interval grove 2007 Ilgrove 2007 Ilgrove 2007 ndvall 2012 oled adiction Interval guera 2016	benefit benefit benefit benefit benefit benefit benefit cost cost cost cost cost	-0.300 0.123 -0.011 -0.004 0.464 2.934 0.278 0.278 0.208 1.045 -0.598 -0.028 0.166	0.318 0.217 0.137 0.111 0.286 0.235 0.471 0.188 0.354 0.239 0.295 0.239	0.101 0.047 0.019 0.022 0.082 0.055 0.221 0.035 0.126 0.057 0.087 0.057	-0.923 -0.303 -0.279 -0.219 -0.764 0.002 2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	0.323 0.548 0.258 0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	-0.943 0.565 -0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.345 0.572 0.939 0.991 0.475 0.049 0.000 0.139 0.557 0.000 0.043 0.907				╵┥┧╴╵		_ ^ ~
benefit Orteg benefit Reute benefit Schul benefit Schul benefit Thirm benefit Thirm benefit Prodic benefit Prodic cost Beligr cost Beligr cost Lundw cost Prodic fanker Angue Ranker Fan 2	lega-Mora 2021 uter 2007 huiz 2012 bin 2004 imm 2010 imm 2011 oled adiction Interval Ilgrove 2007 Ilgrove 2009 ndwell 2012 ndwell 2012 oled adiction Interval guera 2016	benefit benefit benefit benefit benefit benefit cost cost cost cost cost	0.123 -0.011 -0.001 -0.204 0.464 2.934 0.278 0.278 0.208 1.045 -0.598 -0.028 0.166	0.217 0.137 0.111 0.286 0.235 0.471 0.188 0.354 0.239 0.295 0.239	0.047 0.019 0.012 0.082 0.055 0.221 0.035 0.126 0.057 0.087 0.057	-0.303 -0.279 -0.219 -0.764 0.002 2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	0.548 0.258 0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	0.565 -0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.572 0.939 0.991 0.475 0.049 0.000 0.139 0.557 0.000 0.043 0.907				┝ <u>╽</u> ┙║┿╶║		_ ^ Ĩ_ ↑
benefit Reuf- benefit Schul benefit Schul benefit Schul benefit Thimm benefit Produ cost Beligr cost Beligr cost Lundy cost Lundy cost Produ cost Produ cost Produ cost Produ Fanker Angue	uter 2007 hulz 2012 bin 2004 imm 2010 oled adiction Interval Ilgrove 2007 Ilgrove 2009 ndwall 2012 oled adiction Interval guera 2016	benefit benefit benefit benefit benefit cost cost cost cost cost cost	-0.011 -0.001 -0.204 0.464 2.934 0.278 0.278 0.278 0.208 1.045 -0.598 -0.028 0.166	0.137 0.111 0.286 0.235 0.471 0.188 0.354 0.239 0.295 0.239	0.019 0.012 0.082 0.055 0.221 0.035 0.126 0.057 0.087 0.057	-0.279 -0.219 -0.764 0.002 2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	0.258 0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	-0.077 -0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.939 0.991 0.475 0.049 0.000 0.139 0.557 0.000 0.043 0.907						_ ^ 1
benefit Schul benefit Schin benefit Thimm benefit Thimm benefit Poole benefit Poole benefit Poole benefit Bellgr cost Bellgr cost Lundv cost Lundv cost Poole cost Predic Flanker Angue Flanker Zarey	hulz 2012 bin 2004 imm 2010 imm 2011 oled sidicion Interval Ilgrove 2009 ndwall 2012 ndwall 2017 oled sidicion Interval guera 2016	benefit benefit benefit benefit cost cost cost cost cost	-0.001 -0.204 0.464 2.934 0.278 0.278 0.208 1.045 -0.598 -0.028 0.166	0.111 0.286 0.235 0.471 0.188 0.354 0.239 0.295 0.239	0.012 0.082 0.055 0.221 0.035 0.126 0.057 0.087 0.057	-0.219 -0.764 0.002 2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	0.217 0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	-0.011 -0.715 1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.991 0.475 0.049 0.000 0.139 0.557 0.000 0.043 0.907	Ļ					_ ^ 1
benefit Sobin benefit Thimm benefit Thimm benefit Predit cost Beligr cost Beligr cost Lundy cost Lundy cost Poole cost Po	bin 2004 imm 2010 imm 2011 oled ediction Interval Ilgrove 2007 Ilgrove 2009 ndwall 2012 ndwall 2017 oled adiction Interval guera 2016	benefit benefit cost cost cost cost	-0.204 0.464 2.934 0.278 0.278 0.208 1.045 -0.598 -0.028 0.166	0.286 0.235 0.471 0.188 0.354 0.239 0.295 0.239	0.082 0.055 0.221 0.035 0.126 0.057 0.087 0.057	-0.764 0.002 2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	0.356 0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	-0.715 1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.475 0.049 0.000 0.139 0.557 0.000 0.043 0.907	Ļ					
benefit Thimm benefit Thimm benefit Poole benefit Product cost Bellgr cost Bellgr cost Lundv cost Poole Cost Predic Flanker Angue Flanker Zareys	imm 2010 imm 2011 oled sdiction Interval IIgrove 2007 IIgrove 2009 ndwall 2012 ndwall 2017 oled sdiction Interval guera 2016	benefit benefit cost cost cost cost cost	0.464 2.934 0.278 0.278 0.208 1.045 -0.598 -0.028 0.166	0.235 0.471 0.188 0.354 0.239 0.295 0.239	0.055 0.221 0.035 0.126 0.057 0.087 0.087	0.002 2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	0.925 3.857 0.646 1.507 0.903 1.513 -0.020 0.440	1.970 6.237 1.479 0.588 4.377 -2.027 -0.117	0.049 0.000 0.139 0.557 0.000 0.043 0.907	Ļ	-				
benefit Thimm benefit Prodic cost Beligy cost Beligy cost Lundw cost Lundw cost Poole cost Prodic Ranker Angue Ranker Fan 2 Zarey,	imm 2011 oled sdiction Interval Ilgrove 2007 Ilgrove 2009 ndwall 2012 ndwall 2017 oled sdiction Interval guera 2016	benefit cost cost cost cost cost	2.934 0.278 0.278 0.208 1.045 -0.598 -0.028 0.166	0.471 0.188 0.354 0.239 0.295 0.239	0.221 0.035 0.126 0.057 0.087 0.087	2.012 -0.090 -0.952 -0.486 0.577 -1.176 -0.496	3.857 0.646 1.507 0.903 1.513 -0.020 0.440	6.237 1.479 0.588 4.377 -2.027 -0.117	0.000 0.139 0.557 0.000 0.043 0.907	Ļ					
benefit Poole benefit Prodi cost Bellgr cost Bellgr cost Lundv cost Lundv cost Poole Ranker Angu Planker Fan 2	oled adiction Interval Ilgrove 2007 Ilgrove 2009 ndwall 2012 ndwall 2017 oled adiction Interval guera 2016	coat coat coat	0.278 0.278 0.208 1.045 -0.598 -0.028 0.166	0.188 0.354 0.239 0.295 0.239	0.035 0.126 0.057 0.087 0.057	-0.090 -0.952 -0.486 0.577 -1.176 -0.496	0.646 1.507 0.903 1.513 -0.020 0.440	1.479 0.588 4.377 -2.027 -0.117	0.139 0.557 0.000 0.043 0.907	Ļ			-		
benefit Predic cost Bellgr cost Bellgr cost Lundv cost Prodic Cost Predic Flanker Angue Ranker Fan 2 Zarey	ediction Interval Ilgrove 2007 Ilgrove 2009 ndwall 2012 ndwall 2017 oled adiction Interval guera 2016	cost Cost	0.278 0.208 1.045 -0.598 -0.028 0.166	0.354 0.239 0.295 0.239	0.126 0.057 0.087 0.057	-0.952 -0.486 0.577 -1.176 -0.496	1.507 0.903 1.513 -0.020 0.440	0.588 4.377 -2.027 -0.117	0.557 0.000 0.043 0.907	Ļ	-			_	
cost Bell ^a g cost Lundv cost Lundv cost Poole cost Predic Ranker Fan 2 Ranker Zarey	Ilgrove 2009 ndwall 2012 ndwall 2017 oled ediction Interval guera 2016	cost Cost	1.045 -0.598 -0.028 0.166	0.239 0.295 0.239	0.057 0.087 0.057	0.577 -1.176 -0.496	1.513 -0.020 0.440	4.377 -2.027 -0.117	0.000 0.043 0.907						\rightarrow
cost Lundv cost Lundv ost Poole cost Predic Ranker Arguu Ranker Fan 2 Ranker Zareya	ndwall 2012 ndwall 2017 oled ediction Interval guera 2016	cost	-0.598 -0.028 0.166	0.295 0.239	0.087 0.057	-1.176 -0.496	-0.020 0.440	-2.027 -0.117	0.043 0.907	<	╺╸┝			_	\rightarrow
cost Lundw cost Poole cost Predii Flanker Angue Flanker Fan 2 Flanker Zareye	ndwall 2017 oled ediction Interval guera 2016	œa	-0.028 0.166	0.239	0.057	-0.496	0.440	-0.117	0.907	<	╺╸┝╴			_	
cost Poole cost Predic Flanker Angue Flanker Fan 2 Flanker Zareye	oled ediction Interval guera 2016		0.166											-	
cost Predic Flanker Angue Flanker Fan 2 Flanker Zareya	ediction Interval guera 2016	Fanker		0.363	0 132	-0 545	0.077								
Flanker Angue Flanker Fan 2 Flanker Zareya	guera 2016	Flanker	0 166					0.459	0.647						-
Flanker Fan 2 Flanker Zareya		Flanker				-3.104	3.436			×	_				
Flanker Zareya	n 2003		-0.425	0.333	0.111	-1.077	0.227	-1.278	0.201	<hr/>					
		Flanker	0.854	0.538	0.289	-0.201	1.908	1.587	0.112						
	reyan 2021	Flanker	-0.237	0.171	0.029	-0.572	0.097	-1.391	0.164						
Flanker Poole			-0.101	0.272	0.074	-0.633	0.432	-0.370	0.711	-					
	ediction Interval		-0.101 -0.334	0.327	0.107	-5.682 -0.975	5.481 0.307	-1.020	0.308						-1
	emenok 2019 ven 2015	gap effect gap effect	-0.334	0.327	0.107	-0.975	0.589	0.877	0.308				_		
	se 2019	gap effect	0.162	0.208	0.043	-0.225	0.569	0.067	0.380			_			
gap effect Poole		gap ellect	0.029	0.234	0.003	-0.254	0.311	0.198	0.843						
	ediction Interval		0.020	0.144	0.021	-0.204	0.011	0.150	0.040						
	mish 2007	valid orienting RT	0.498	0.407	0.165	-0.299	1.295	1.225	0.221						\rightarrow
	an 2017	valid orienting RT	0.197	0.235	0.055	-0.263	0.657	0.839	0.402					_ <u>T</u>	-
valid orienting RT Poole			0.272	0.203	0.041	-0.126	0.670	1.339	0.181			_			
valid orienting RT Predic	ediction Interval														
	ah 2007	validity effect	0.437	0.369	0.137	-0.287	1.161	1.183	0.237						→
validity effect Couet	uette 2008	validity effect	0.894	0.396	0.157	0.117	1.671	2.256	0.024						∎→
	eenwood 2005	validity effect	0.431	0.169	0.029	0.099	0.763	2.548	0.011						
	wman 2014	validity effect	0.064	0.176	0.031	-0.282	0.409	0.361	0.718				-	-	
	rasuraman 2005	validity effect	-0.053	0.273	0.074	-0.587	0.482	-0.194	0.846				_	_	
	intero 2014	validity effect	0.178	0.237	0.056	-0.287	0.643	0.751	0.453			-			
	hneider 2015	validity effect	-1.429	0.242	0.059	-1.904	-0.953	-5.893	0.000	•					
	non 2005	validity effect	1.920	0.467	0.218	1.004	2.836	4.110	0.000						2
	ai 1995	validity effect	0.601	0.292	0.085	0.028	1.173	2.056	0.040						
validity effect Poole	oled ediction Interval		0.283 0.283	0.251	0.063	-0.209 -1.459	0.775 2.025	1.126	0.260						
validity effect Predic Overall Poole			0.283	0.080	0.006	-1.459	2.025	1.376	0.169						1
	ored ediction Interval		0.110	0.000	0.000	-0.047	1.105	1.370	0.109						
Fibul	saroaon mitorval		0.110			0.000	1.100			-1.00	-0.50	0.	00	0.50	1.00
											Uset PC 1			Law Diale	
											High Risk			Low Risk	

oup by jeGrp	Study name	Outcome			Statistics for		udy	Std diff	in means and 95	<u>% CI</u>			
jeap			Std diff in means	Standard error	Variance	Lower limit	Upper limit	Z-Value	p-Value				
ult	Chernenok 2019	gap effect	-0.334	0.327	0.107	-0.975	0.307	-1.020	0.308	I			1
ult	Cornish 2007	valid orienting RT	0.498	0.407	0.165	-0.299	1.295	1.225	0.221				
ult	Espeseth 2007	AUD Cz, target amplitude	-0.382	0.418	0.175	-1.202	0.438	-0.913	0.361	<			— T
ult	Fan 2003	Flanker	0.854	0.538	0.289	-0.201	1.908	1.587	0.112				
ult	Gallinat 2003	AUD Cz, target amplitude	0.064	0.235	0.055	-0.397	0.525	0.272	0.786		<u> </u>		
ult	Gallinat 2007	AUD Cz, target amplitude	0.687	0.184	0.034	0.325	1.048	3.723	0.000			-	
ult	Gao 2018	AUD Cz, target amplitude	-0.710	0.316	0.100	-1.329	-0.091	-2.247	0.025	< ─	_	—	
ult	Greenwood 2005	validity effect	0.431	0.169	0.029	0.099	0.763	2.548	0.011	_			
ult	Lundwall 2012	cost	-0.598	0.295	0.087	-1.176	-0.020	-2.027	0.043	<			_
ult	Mannarelli 2018	AUD Cz, target amplitude	0.113	0.448	0.200	-0.764	0.990	0.252	0.801				
ult	Marco-Pallarés 2010	AUD Cz, target amplitude	-1.294	0.328	0.108	-1.936	-0.651	-3.945	0.000	←	1	1 -	
ult	Maurage 2017	benefit	-0.300	0.318	0.101	-0.923	0.323	-0.943	0.345				.
ult	New man 2014	validity effect	0.064	0.176	0.031	-0.282	0.409	0.361	0.718		_		_
ult	O'Donoghue 2014	AUD Cz, target amplitude	0.195	0.206	0.042	-0.209	0.599	0.948	0.343		.		-+
ult	Ortega-Mora 2021	benefit	0.123	0.217	0.047	-0.303	0.548	0.565	0.572		I —		
ult	Parasuraman 2005	validity effect	-0.053	0.273	0.047	-0.587	0.482	-0.194	0.846				
ult	Reuter 2007	benefit	-0.000	0.273	0.014	-0.279	0.462	-0.077	0.939				
ult	Schneider 2015	validity effect	-1.429	0.137	0.019	-1.904	-0.953	-5.893	0.000	-	1 -	T	
ult	Schulz 2012	benefit	-0.001	0.242	0.039	-0.219	0.217	-0.011	0.991	r i	1.		
ult	Thimm 2010	benefit	0.464	0.111	0.012	0.002	0.217	1.970	0.049		1		_
ult	Thimm2010	benefit	2.934	0.235	0.033	2.012	3.857	6.237	0.000				_
ult	Tsai 1995	validity effect	0.601	0.292	0.085	0.028	1.173 0.097	2.056	0.040				
ult	Zareyan 2021	Flanker	-0.237	0.171	0.029	-0.572		-1.391	0.164				
ult	Pooled		0.034	0.123	0.015	-0.208	0.275	0.273	0.785	1.			
ult	Prediction Interval		0.034			-1.074	1.142			<u> </u>			
ild	Anguera 2016	Flanker	-0.425	0.333	0.111	-1.077	0.227	-1.278	0.201				
ild	Bellgrove 2007	cost	0.208	0.354	0.126	-0.486	0.903	0.588	0.557				
ild	Bellgrove 2009	cost	1.045	0.239	0.057	0.577	1.513	4.377	0.000			_	
ild	Birkas 2006	AUD Cz, target amplitude	-0.143	0.309	0.096	-0.749	0.464	-0.461	0.645				_
ild	Bish 2007	validity effect	0.437	0.369	0.137	-0.287	1.161	1.183	0.237				
ild	Couette 2008	validity effect	0.894	0.396	0.157	0.117	1.671	2.256	0.024				
ild	Lundwall 2017	cost	-0.028	0.239	0.057	-0.496	0.440	-0.117	0.907				-
ild	Markant 2014	benefit	0.197	0.256	0.065	-0.304	0.698	0.771	0.441		-		
ild	Ow en 2015	gap effect	0.182	0.208	0.043	-0.225	0.589	0.877	0.380				-+
ild	Quan 2017	valid orienting RT	0.197	0.235	0.055	-0.263	0.657	0.839	0.402		-		
ild	Quintero 2014	validity effect	0.178	0.237	0.056	-0.287	0.643	0.751	0.453		- I		
ild	Rose 2019	gap effect	0.017	0.254	0.065	-0.481	0.515	0.067	0.946		I		\rightarrow
ild	Simon 2005	validity effect	1.920	0.467	0.218	1.004	2.836	4.110	0.000		1		
ild	Sobin 2004	benefit	-0.204	0.286	0.082	-0.764	0.356	-0.715	0.475	I —			-
ild	Pooled		0.270	0.129	0.017	0.017	0.522	2.092	0.036		1 -		
ild	Prediction Interval		0.270			-0.609	1.148						
rerall	Pooled		0.146	0.089	0.008	-0.028	0.321	1.643	0.100	1			.
erall	Prediction Interval		0.146			-0.852	1.145			I H	_	-	
										1.00	-0.50	0.00	0.50
											-0.00	0.00	0.50
											tale Diale		1 F*
										H	igh Risk		Low Ris
RE 6													
-													

Group analyses

Outcome type

The overall heterogeneity in outcome types in our meta-analysis was moderate. However, several outcomes had high within-outcome heterogeneity (such AUD Cz, costs, and validity effect). While this might mean that these measures do not measure the same construct across studies, it could also mean that the studies vary for other reasons, such as sampling from different populations or assessing different genes. The remaining outcome measures had low or moderate within-outcome heterogeneity. Overall, out meta-analysis offers some support for the idea that the different ways of measuring RA are related, as theory implies (Lyytinen et al., 2002; Posner, 1980; Sokolov, 1963, 1966; Voronin and Sokolov, 1960). Since we found no other studies that tested this idea, this may be an important contribution.

Related is the question, "which measures were more often successful at detecting differences in RA?" Examining Figure 5 again, we see that outcomes with pooled effects in the opposite direction from expected include AUD Cz target amplitude and flanker congruency effect. Some outcomes also had a smaller proportion of studies producing significant effects (i.e., flanker, gap effect, and valid RT). Only validity effect had more than half its studies producing significant results, and one was in the unexpected direction. Overall, validity effect seems to be slightly better at detecting the influence of genes on RA, although its pooled effect size is not significant.

Age group

Our most interesting finding is that estimates of effect size differed by age group. Children had effect sizes significantly different from zero while adults did not. This suggests that studies of genetic influence on RA is children is more apparent in children. It is likely that the same genotype has different influences on phenotype across development (Markant et al., 2014; Tang et al., 2020). For example, we know that RA develops in tandem with cholinergic and dopaminergic polymorphisms expressed during early life (Burstein et al., 2021; Markant et al., 2014; McKinnon and Nathanson, 1995). Had the same genotypes been tested at multiple ages, ideally in a longitudinal study, it would be possible to determine if the same genotype exerts a stronger influence on RA at different points in the lifespan.

We were not able to find a similar effect size for genetic influence on adult RA. One possibility is that there were four studies with considerable effects in the opposite direction of the expected effect in the adult age group. Two were AUD Cz studies (Gao et al., 2018; Marco-Pallarés et al., 2010). Since AUD Cz was likely to be an outcome in child studies, this may represent a confound. Another possibility is that a genotype thought to be an advantage at one age is not an advantage at another age. One illustration of this general concept is that some studies suggest that the APOE ε 4 variant, typically associated with Alzheimer's disease, may confer cognitive advantages in younger individuals (Oriá et al., 2010; Wright et al., 2003; van Exel et al., 2017).

cost cost ALD C2, target amplitude Panker ALD C2, target amplitude Cost cost Cost ALD C2, target amplitude 21 benefit Donefit benefit b	0.854 -0.710 0.431 -0.598 -0.028 0.113 0.064 0.195 0.123 -0.053 0.197 -1.429 -0.001 0.464 2.534 0.144 0.144 0.144	Standard error 0.354 0.239 0.418 0.538 0.366 0.538 0.366 0.538 0.316 0.299 0.448 0.176 0.206 0.217 0.235 0.442 0.111 0.235 0.441 0.170 0.273 0.245 0.441 0.1205 0.442 0.111 0.235 0.471 0.150 0.333 0.309 0.327 0.407	Variance 0.126 0.057 0.175 0.289 0.000 0.029 0.087 0.200 0.031 0.057 0.200 0.031 0.047 0.074 0.055 0.029 0.047 0.059 0.012 0.059 0.012 0.059 0.022 0.022	Lower limit -0.486 0.577 -1.202 -0.201 -1.329 0.099 -1.176 -0.496 -0.764 -0.282 -0.209 -0.303 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.097 -0.749	Upper limit 0.903 1.513 0.438 1.908 -0.021 0.440 0.909 0.599 0.548 0.409 0.599 0.548 0.409 0.595 0.407 -0.953 0.217 0.437 1.3857 0.437 1.3857 0.227	Z-Value 0.588 4.377 -0.913 1.587 -2.247 -0.173 0.252 0.361 0.948 0.565 -0.194 0.839 -5.833 -0.011 1.970 6.237 0.961	p-Value 0.557 0.000 0.361 0.112 0.025 0.011 0.043 0.907 0.801 0.718 0.343 0.572 0.840 0.343 0.572 0.402 0.402 0.400 0.991 0.499 0.0386 0.336 0.336 0.201	• • • • •	• • •			
cost ALD C2, target amplitude Flanker ALD C2, target amplitude cost cost addity effect cost addity effect validity effect benefit benefit benefit benefit benefit validity effect	1.045 -0.382 0.854 -0.710 0.431 -0.598 0.025 0.025 0.013 0.064 0.123 0.064 0.123 0.064 0.123 0.064 0.123 0.057 0.123 0.057 0.123 0.057 0.123 0.059 0.123 0.059 0.123 0.059 0.123 0.059 0.123 0.059 0.123 0.059 0.123 0.059 0.123 0.059 0.123 0.0590000000000	0.239 0.418 0.538 0.316 0.229 0.428 0.476 0.273 0.225 0.242 0.411 0.255 0.242 0.411 0.150 0.333 0.339 0.339 0.369 0.369	0.057 0.175 0.289 0.000 0.067 0.057 0.057 0.042 0.042 0.042 0.044 0.055 0.059 0.015 0.055 0.059 0.015 0.055 0.221 0.055 0.221 0.052	0.577 -1.202 -0.201 -1.329 0.099 -1.176 -0.496 -0.764 -0.282 -0.209 -0.303 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.097 -0.749	1.513 0.438 1.908 -0.091 0.763 -0.020 0.409 0.599 0.599 0.409 0.599 0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383	4.377 -0.913 1.587 -2.248 -2.027 -0.117 0.252 0.361 0.948 0.565 -0.194 0.839 -0.833 -0.011 1.970 6.237 0.961	0.000 0.361 0.112 0.025 0.011 0.907 0.801 0.718 0.343 0.572 0.840 0.343 0.572 0.840 0.402 0.402 0.400 0.991 0.049 0.049 0.049 0.049 0.049	* * *	•			
cost ALD C2, target amplitude Flanker ALD C2, target amplitude cost cost addity effect cost addity effect validity effect benefit benefit benefit benefit benefit validity effect	1.045 -0.382 0.854 -0.710 0.431 -0.598 0.025 0.025 0.013 0.064 0.123 0.064 0.123 0.064 0.123 0.064 0.123 0.057 0.123 0.057 0.123 0.057 0.123 0.059 0.123 0.059 0.123 0.059 0.123 0.059 0.123 0.059 0.123 0.059 0.123 0.059 0.123 0.059 0.123 0.0590000000000	0.239 0.418 0.538 0.316 0.229 0.428 0.476 0.273 0.225 0.242 0.411 0.255 0.242 0.411 0.150 0.333 0.339 0.339 0.369 0.369	0.057 0.175 0.289 0.000 0.067 0.057 0.057 0.042 0.042 0.042 0.044 0.055 0.059 0.015 0.055 0.059 0.015 0.055 0.221 0.055 0.221 0.052	0.577 -1.202 -0.201 -1.329 0.099 -1.176 -0.496 -0.764 -0.282 -0.209 -0.303 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.097 -0.749	1.513 0.438 1.908 -0.091 0.763 -0.020 0.409 0.599 0.599 0.409 0.599 0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383	4.377 -0.913 1.587 -2.248 -2.027 -0.117 0.252 0.361 0.948 0.565 -0.194 0.839 -0.833 -0.011 1.970 6.237 0.961	0.000 0.361 0.112 0.025 0.011 0.907 0.801 0.718 0.343 0.572 0.840 0.343 0.572 0.840 0.402 0.402 0.400 0.991 0.049 0.049 0.049 0.049 0.049	* * *	• • •			
ALD C2, target amplitude Planker ALD C2, target amplitude validity effect cost a ALD C2, target amplitude validity effect bardity effect valid orienting RT valid valid effect benefit benefit benefit benefit valid y effect valid y effect valid y effect benefit benefit benefit benefit valid y effect valid y effect	0.854 -0.710 0.431 -0.588 -0.028 -0.0113 0.064 -0.113 -0.053 0.015 -0.123 -0.019 -0.019 -0.001 0.464 0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.144 -0.195 -0.001 -0.	0.538 0.316 0.169 0.295 0.239 0.248 0.176 0.227 0.273 0.242 0.217 0.273 0.242 0.241 0.111 0.255 0.242 0.471 0.150 0.333 0.309 0.3369 0.327	0.175 0.289 0.100 0.029 0.087 0.067 0.200 0.031 0.047 0.047 0.059 0.059 0.059 0.059 0.059 0.022 0.052 0.221 0.052	-1.202 -0.201 -1.329 0.099 -1.176 -0.496 -0.764 -0.262 -0.209 -0.303 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.097 -0.749	0.438 1.908 -0.091 0.763 -0.020 0.440 0.990 0.599 0.599 0.599 0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383	-0.913 1.587 -2.247 2.548 2.027 -0.117 0.252 0.361 0.948 0.565 -0.194 0.893 -0.883 -0.011 1.970 6.237 0.961	0.361 0.112 0.025 0.011 0.043 0.801 0.801 0.801 0.801 0.846 0.402 0.846 0.402 0.991 0.991 0.049 0.000 0.336	* * *				■→
Flanker ALD Cz., target amplitude 05 validity effect cost cost 3 ALD Cz., target amplitude validity effect validity effect valid orienting RT valid ty effect validity effect validity effect valid ty effect valid ty effect validity effect validity effect validity effect benefit benefit benefit validity effect validity effect validity effect valid ty effect valid ty effect valid ty effect	0.854 -0.710 0.431 -0.588 -0.028 -0.0113 0.064 -0.113 -0.058 -0.0195 -0.123 -0.0195 -0.123 -0.019 -0.001 -0.454 -0.454 -0.454 -0.454 -0.455 -0.144 -0.425 -0.144 -0.425 -0.0144 -0.437 -0.0334 -0.0334 -0.0334 -0.034 -0	0.316 0.169 0.285 0.239 0.448 0.176 0.217 0.217 0.217 0.215 0.242 0.111 0.235 0.242 0.111 0.235 0.471 0.150 0.333 0.309 0.339	0.100 0.029 0.057 0.200 0.031 0.042 0.047 0.074 0.055 0.059 0.012 0.055 0.221 0.022 0.111 0.022	-1.329 0.099 -1.176 -0.496 -0.764 -0.282 -0.209 -0.303 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.097 -0.749	-0.091 0.763 -0.020 0.440 0.990 0.599 0.548 0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383	-2.247 2.548 -2.027 -0.17 0.252 0.361 0.948 0.565 -0.194 0.839 -5.893 -0.011 1.970 6.237 0.961	0.025 0.011 0.043 0.907 0.801 0.718 0.343 0.572 0.846 0.402 0.000 0.991 0.049 0.000 0.336	< < ▼	•			■→
05 validity effect cost cost cost validity effect 14 ALD C2, target amplitude validity effect 12 benefit 005 validity effect valid orienting RT validity effect benefit benefit validity effect validity effect	0.431 -0.598 -0.028 -0.028 -0.013 -0.064 -0.193 -0.053 -0.053 -0.053 -0.053 -0.053 -0.053 -0.053 -0.123 -0.053 -0.123 -0.053 -0.123 -0.053 -0.123 -0.054 -0.123 -0.054 -0.123 -0.054 -0.123 -0.054 -0.123 -0.054 -0.123 -0.054 -0.123 -0.054 -0.123 -0.054 -0.123 -0.054 -0.123 -0.054 -0.123 -0.055 -0.123 -0.053 -0.123 -0.053 -0.053 -0.053 -0.054 -0.123 -0.053 -0.053 -0.054 -0.123 -0.053 -0.054 -0.123 -0.054 -0.055 -0.123 -0.055 -0.123 -0.054 -0.055 -0.123 -0.055 -0.123 -0.054 -0.055 -0.123 -0.055 -0.123 -0.054 -0.055 -0.123 -0.055 -0.123 -0.054 -0.055 -0.123 -0.055 -0.124 -0.055 -0.124 -0.055 -0.124 -0.054 -0.	0.169 0.295 0.239 0.448 0.176 0.226 0.217 0.273 0.225 0.242 0.111 0.225 0.471 0.150 0.333 0.309 0.339 0.369	0.029 0.087 0.057 0.200 0.031 0.042 0.047 0.074 0.055 0.055 0.221 0.022 0.012 0.022 0.111 0.022	0.099 -1.176 -0.496 -0.764 -0.282 -0.203 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.096 -1.077 -0.749	0.763 -0.020 0.440 0.990 0.599 0.548 0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383	2.548 -2.027 -0.117 0.252 0.361 0.948 0.565 -0.194 0.839 -5.893 -0.011 1.970 6.237 0.961	0.011 0.043 0.907 0.801 0.718 0.343 0.572 0.846 0.402 0.000 0.991 0.049 0.000 0.336	*				_
05 validity effect cost cost cost validity effect 14 ALD C2, target amplitude validity effect 12 benefit 005 validity effect valid orienting RT validity effect benefit benefit validity effect validity effect	0.431 -0.596 -0.028 -0.013 0.064 -0.013 -0.053 -0.053 -0.053 -0.053 -0.053 -0.053 -0.053 -0.044 -0.425 -0.044 -0.444 -0.425 -0.143 -0.334 -0.123 -0.053 -0.123 -0.053 -0.123 -0.053 -0.123 -0.053 -0.123 -0.053 -0.123 -0.053 -0.123 -0.053 -0.123 -0.054 -0.123 -0.053 -0.123 -0.054 -0.123 -0.053 -0.123 -0.053 -0.054 -0.123 -0.053 -0.053 -0.054 -0.054 -0.053 -0.053 -0.054 -0.054 -0.055 -0.123 -0.053 -0.054 -0.054 -0.054 -0.054 -0.055 -0.123 -0.054 -0.0554 -0.054 -0.0554	0.295 0.239 0.448 0.176 0.206 0.217 0.273 0.235 0.242 0.111 0.235 0.471 0.150 0.333 0.309 0.389 0.327	0.029 0.087 0.057 0.200 0.031 0.042 0.047 0.074 0.055 0.055 0.221 0.022 0.012 0.022 0.111 0.022	-1.176 -0.496 -0.764 -0.282 -0.209 -0.303 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.096 -1.077 -0.749	-0.020 0.440 0.990 0.599 0.548 0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383	-2.027 -0.117 0.252 0.361 0.948 0.565 -0.194 0.8393 -0.011 1.970 6.237 0.961	0.043 0.907 0.801 0.718 0.343 0.572 0.846 0.402 0.000 0.991 0.049 0.000 0.336	×	- 			_
cost cost 3 ALD C2, target amplitude validity effect 4 ALD C2, target amplitude 21 benefit valid orienting RT validity effect benefit benefit benefit benefit validity effect validity effect validity effect validity effect validity effect validity effect valid orienting RT validity effect valid orienting RT	-0.598 -0.028 -0.028 -0.113 -0.064 -0.195 -0.195 -0.197 -1.429 -0.001 -0.464 2.934 -0.144 -0.464 2.934 -0.144 -0.425 -0.144 -0.425 -0.0144 -0.425 -0.034 -0.437 -0.334 -0.438	0.239 0.448 0.176 0.206 0.217 0.273 0.242 0.111 0.255 0.442 0.111 0.150 0.333 0.309 0.339 0.339	0.087 0.057 0.200 0.031 0.042 0.047 0.055 0.059 0.012 0.055 0.221 0.022 0.1111	-0.496 -0.764 -0.282 -0.209 -0.303 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.096 -1.077 -0.749	-0.020 0.440 0.990 0.599 0.548 0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383	-0.117 0.252 0.361 0.948 0.565 -0.194 0.839 -5.893 -0.011 1.970 6.237 0.961	0.043 0.907 0.801 0.718 0.343 0.572 0.846 0.402 0.000 0.991 0.049 0.000 0.336	•				_
ALD Cz, target amplitude validity effect ALD Cz, target amplitude validity effect validity effect validity effect benefit benefit benefit benefit benefit benefit validity effect valid orienting RT valid orienting RT	0.113 0.064 0.195 0.123 0.097 -1.429 -0.001 0.464 2.934 0.144 0.144 -0.425 -0.143 0.437 -0.334 0.498	0.448 0.176 0.206 0.217 0.273 0.235 0.242 0.111 0.235 0.471 0.150 0.333 0.309 0.369 0.327	0.200 0.031 0.042 0.047 0.055 0.059 0.012 0.055 0.221 0.022 0.111 0.096 0.137	-0.764 -0.282 -0.209 -0.303 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.096 -1.077 -0.749	0.990 0.409 0.599 0.548 0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383	0.252 0.361 0.948 0.565 -0.194 0.839 -5.893 -0.011 1.970 6.237 0.961	0.801 0.718 0.343 0.572 0.846 0.402 0.000 0.991 0.049 0.000 0.336	¥				_
validity effect 14 ALD C2, target ampitude 21 benefit 23 validity effect 24 orening RT 25 validity effect 26 benefit 27 benefit 28 benefit 29 gap effect 29 gap effect 29 gap effect 29 gap effect 20 validity effect	0.064 0.195 0.123 -0.053 0.197 -1.429 -0.001 0.464 2.934 0.144 -0.425 -0.143 0.437 -0.334 0.437	0.176 0.206 0.217 0.273 0.235 0.242 0.111 0.235 0.471 0.150 0.333 0.309 0.369 0.327	0.031 0.042 0.047 0.055 0.059 0.012 0.055 0.221 0.022 0.111 0.096 0.137	-0.282 -0.209 -0.303 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.096 -1.077 -0.749	0.409 0.599 0.548 0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383	0.361 0.948 0.565 -0.194 0.839 -5.893 -0.011 1.970 6.237 0.961	0.718 0.343 0.572 0.846 0.402 0.000 0.991 0.049 0.000 0.336	¥				_
14 ALD Cz, target amplitude 121 benefit 1221 benefit 1231 benefit 1242 benefit 1243 benefit 1244 Ffect 1244 Benefit 1244 Benefit </td <td>0.195 0.123 -0.053 0.197 -1.429 -0.001 0.464 2.934 0.144 0.144 0.144 0.144 0.143 0.143 0.425 -0.143 0.437 -0.334 0.436</td> <td>0.206 0.217 0.273 0.235 0.242 0.111 0.235 0.471 0.150 0.333 0.309 0.369 0.369 0.327</td> <td>0.042 0.047 0.074 0.055 0.059 0.012 0.055 0.221 0.022 0.111 0.096 0.137</td> <td>-0.209 -0.303 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.096 -1.077 -0.749</td> <td>0.599 0.548 0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383</td> <td>0.948 0.565 -0.194 0.839 -5.893 -0.011 1.970 6.237 0.961</td> <td>0.343 0.572 0.846 0.402 0.000 0.991 0.049 0.000 0.336</td> <td>¥</td> <td></td> <td></td> <td></td> <td>_</td>	0.195 0.123 -0.053 0.197 -1.429 -0.001 0.464 2.934 0.144 0.144 0.144 0.144 0.143 0.143 0.425 -0.143 0.437 -0.334 0.436	0.206 0.217 0.273 0.235 0.242 0.111 0.235 0.471 0.150 0.333 0.309 0.369 0.369 0.327	0.042 0.047 0.074 0.055 0.059 0.012 0.055 0.221 0.022 0.111 0.096 0.137	-0.209 -0.303 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.096 -1.077 -0.749	0.599 0.548 0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383	0.948 0.565 -0.194 0.839 -5.893 -0.011 1.970 6.237 0.961	0.343 0.572 0.846 0.402 0.000 0.991 0.049 0.000 0.336	¥				_
121 benefit 0005 validity effect validity effect benefit benefit benefit benefit benefit validity effect validity effect 9 qap effect validity effect validity effect validity effect validity effect	0.123 -0.053 0.197 -1.429 -0.001 0.464 2.934 0.144 0.144 -0.425 -0.143 0.437 -0.334 0.498	0.217 0.273 0.235 0.242 0.111 0.235 0.471 0.150 0.333 0.309 0.369 0.369	0.047 0.074 0.055 0.059 0.012 0.055 0.221 0.022 0.111 0.096 0.137	-0.303 -0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.096 -1.077 -0.749	0.548 0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383	0.565 -0.194 0.839 -5.893 -0.011 1.970 6.237 0.961	0.572 0.846 0.402 0.000 0.991 0.049 0.000 0.336	¥	<u> </u>			_
005 validity effect valid orienting RT valid verfitt benefit benefit val Ranker ALD C2, target amplitude validity effect valid orienting RT valid orienting RT valid y effect	-0.053 0.197 -1.429 -0.001 0.464 2.934 0.144 -0.425 -0.143 0.437 -0.334 0.437	0.273 0.235 0.242 0.111 0.235 0.471 0.150 0.333 0.309 0.369 0.327	0.074 0.055 0.059 0.012 0.055 0.221 0.022 0.111 0.096 0.137	-0.587 -0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.096 -1.077 -0.749	0.482 0.657 -0.953 0.217 0.925 3.857 0.437 1.383	-0.194 0.839 -5.893 -0.011 1.970 6.237 0.961	0.846 0.402 0.000 0.991 0.049 0.000 0.336	¥	+			_
valid orienting RT 5 validly effect benefit benefit benefit benefit benefit Val Ranker ALD Cz, target amplitude validly effect valid orienting RT valid reffect ALD Cz, target amplitude	0.197 -1.429 -0.001 0.464 2.934 0.144 -0.425 -0.143 0.437 -0.334 0.439	0.235 0.242 0.111 0.235 0.471 0.150 0.333 0.309 0.369 0.327	0.055 0.059 0.012 0.055 0.221 0.022 0.111 0.096 0.137	-0.263 -1.904 -0.219 0.002 2.012 -0.150 -1.096 -1.077 -0.749	0.657 -0.953 0.217 0.925 3.857 0.437 1.383	0.839 -5.893 -0.011 1.970 6.237 0.961	0.402 0.000 0.991 0.049 0.000 0.336	¥				_
5 validity effect benefit benefit benefit ALD C2, target ampitude validity effect valid offect valid orienting RT validity effect ALD C2, target ampitude	-1.429 -0.001 0.464 2.934 0.144 0.144 -0.425 -0.143 0.437 -0.334 0.498	0.242 0.111 0.235 0.471 0.150 0.333 0.309 0.369 0.327	0.059 0.012 0.055 0.221 0.022 0.111 0.096 0.137	-1.904 -0.219 0.002 2.012 -0.150 -1.096 -1.077 -0.749	-0.953 0.217 0.925 3.857 0.437 1.383	-5.893 -0.011 1.970 6.237 0.961	0.000 0.991 0.049 0.000 0.336	×			_	_
benefit benefit benefit val Ranker ALD Cz, target amplitude validity effect 9 gap effect valid orienting RT valid orienting RT validity effect ALD Cz, target amplitude	-0.001 0.464 2.934 0.144 -0.425 -0.143 0.437 -0.334 0.498	0.111 0.235 0.471 0.150 0.333 0.309 0.369 0.327	0.012 0.055 0.221 0.022 0.111 0.096 0.137	-0.219 0.002 2.012 -0.150 -1.096 -1.077 -0.749	0.217 0.925 3.857 0.437 1.383	-0.011 1.970 6.237 0.961	0.991 0.049 0.000 0.336	*		-		_
benefit benefit Val Ranker ALD C2, target amplitude validly effect valid orienting RT valid orienting RT valid y effect ALD C2, target amplitude	0.464 2.934 0.144 -0.425 -0.143 0.437 -0.334 0.498	0.235 0.471 0.150 0.333 0.309 0.369 0.327	0.055 0.221 0.022 0.111 0.096 0.137	0.002 2.012 -0.150 -1.096 -1.077 -0.749	0.925 3.857 0.437 1.383	1.970 6.237 0.961	0.049 0.000 0.336					_↓
benefit Flanker AUD C2, target amplitude validity effect 9 gap effect valid orienting RT validity effect AUD C2, target amplitude	2.934 0.144 -0.425 -0.143 0.437 -0.334 0.498	0.471 0.150 0.333 0.309 0.369 0.327	0.221 0.022 0.111 0.096 0.137	2.012 -0.150 -1.096 -1.077 -0.749	3.857 0.437 1.383	6.237 0.961	0.000 0.336					-
AUD C2, target amplitude validity effect gap effect valid orienting RT validity effect AUD C2, target amplitude	0.144 0.144 -0.425 -0.143 0.437 -0.334 0.498	0.150 0.333 0.309 0.369 0.327	0.022 0.111 0.096 0.137	-0.150 -1.096 -1.077 -0.749	0.437 1.383	0.961	0.336					×
Hanker AUD Cz, target amplitude validity effect 9 gap effect valid orienting RT validity effect AUD Cz, target amplitude	0.144 -0.425 -0.143 0.437 -0.334 0.498	0.333 0.309 0.369 0.327	0.111 0.096 0.137	-1.096 -1.077 -0.749	1.383							
Hanker AUD Cz, target amplitude validity effect 9 gap effect valid orienting RT validity effect AUD Cz, target amplitude	-0.425 -0.143 0.437 -0.334 0.498	0.309 0.369 0.327	0.096 0.137	-1.077 -0.749			0.201					
AUD Cz., target amplitude validity effect 9 gap effect valid orienting RT validity effect AUD Cz., target amplitude	-0.143 0.437 -0.334 0.498	0.309 0.369 0.327	0.096 0.137	-0.749	0.227		0.201	⊢		-		→
validity effect 9 gap effect valid orienting RT validity effect AUD Cz, target amplitude	0.437 -0.334 0.498	0.369 0.327	0.137			-1.278	0.201	<				
9 gap effect valid orienting RT validity effect AUD Cz, target amplitude	-0.334 0.498	0.327		0.007	0.464	-0.461	0.645					
valid orienting RT validity effect AUD Cz, target amplitude	0.498			-0.287	1.161	1.183	0.237					\rightarrow
validity effect AUD Cz, target amplitude		0.407	0.107	-0.975	0.307	-1.020	0.308				_	
AUD Cz, target amplitude	0.894	0.407	0.165	-0.299	1.295	1.225	0.221					\rightarrow
		0.396	0.157	0.117	1.671	2.256	0.024					
ALID Cz. target amplitude		0.235	0.055	-0.397	0.525	0.272	0.786					
		0.184	0.034	0.325	1.048	3.723	0.000					\rightarrow
2010 AUD Cz, target amplitude		0.328	0.108	-1.936	-0.651	-3.945	0.000	<	_			
benefit	0.197	0.256	0.065	-0.304	0.698	0.771	0.441		•			
benefit	-0.300	0.318	0.101	-0.923	0.323	-0.943	0.345				_	
gap effect	0.182	0.208	0.043	-0.225	0.589	0.877	0.380					
validity effect	0.178	0.237	0.056	-0.287	0.643	0.751	0.453			━━┼━╋		
benefit	-0.011	0.137	0.019	-0.279	0.258	-0.077	0.939				-	
										_		7
											_	
Flanker									_			
		0.115	0.013			0.932	0.351					
val										-		
		0.091	0.008			1.324	0.185					
val	0.121			-0.879	1.120			- I F				
								-1.00	-0.50	0.00	0.50	1.00
									High Risk		Low Risk	
	gap effect validity effect benefit validity effect Flanker	gap effect 0.017 validity effect 1.520 beneft -0.204 validity effect 0.601 Ranker -0.231 al 0.107 0.107 0.127	gap effect 0.017 0.254 validity effect 1.920 0.467 benefit -0.204 0.286 validity effect 0.601 0.282 Hanker -0.234 0.171 sil 0.107 0.115 0.107 0.121 0.091	gap effect 0.017 0.254 0.065 validity effect 1.920 0.467 0.218 benefit -0.204 0.282 0.082 validity effect 0.601 0.282 0.082 Flanker -0.237 0.171 0.029 al 0.107 0.115 0.013 0.121 0.001 0.282 0.082	gap effect 0.017 0.254 0.065 -0.481 validity effect 1.920 0.467 0.218 1.004 benefit -0.204 0.286 0.082 -0.764 validity effect 0.601 0.282 0.068 -0.764 Planker -0.207 0.171 0.028 -0.764 al 0.107 0.115 0.013 -0.118 ol.107 0.107 0.155 0.078 -0.790	gap effect 0.017 0.254 0.065 -0.481 0.515 validity effect 1.920 0.467 0.218 1.004 2.836 benefit -0.204 0.286 0.082 0.764 0.366 validity effect 0.601 0.282 0.082 0.764 0.366 naker -0.237 0.171 0.029 0.572 0.097 al 0.107 0.115 0.013 -0.118 0.332 al 0.107 -0.790 0.004 0.058 0.278	gap effect 0.017 0.254 0.065 -0.481 0.515 0.067 validity effect 1.920 0.467 0.218 1.004 2.836 4.110 benefit -0.204 0.286 0.082 -0.764 0.366 -0.715 validity effect 0.601 0.282 0.082 0.764 0.366 -0.715 Hanker -0.207 0.171 0.029 0.572 0.097 -1.391 a) 0.107 0.115 0.013 -0.118 0.332 0.932 a) 0.107 0.115 0.031 -0.118 0.332 0.932 a) 0.107 0.115 0.018 -0.769 1.004	gap effect 0.017 0.254 0.065 -0.481 0.515 0.067 0.946 validity effect 1.920 0.467 0.218 1.004 2.836 4.110 0.000 benefit -0.204 0.286 0.0173 0.075 0.715 0.715 0.400 validity effect 0.601 0.232 0.085 0.028 1.173 2.066 0.040 Planker 0.207 0.171 0.029 0.572 0.097 -1.391 0.164 0.107 0.115 0.013 -0.118 0.332 0.932 0.351 al 0.107 0.108 0.068 0.068 0.299 1.324 0.185	gap effect 0.017 0.254 0.065 -0.481 0.515 0.067 0.946 validity effect 1.920 0.467 0.218 1.004 2.836 4.110 0.0000 benefit -0.204 0.288 0.082 -0.746 0.366 -0.715 0.475 validity effect 0.801 0.282 0.082 0.174 0.366 -0.715 0.475 validity effect 0.801 0.232 0.082 0.174 0.392 0.040 Flanker -0.207 0.171 0.029 -0.572 0.097 -1.391 0.164 0.107 0.115 0.032 0.731 0.178 0.332 0.331 al 0.107 -0.790 1.004 -0.790 1.024 -0.783 al 0.121 -0.879 1.220 0.829 1.324 0.185	gap effect 0.017 0.254 0.065 0.481 0.515 0.067 0.946 validity effect 1.920 0.467 0.218 1.004 2.836 4.110 0.000 benefit -0.204 0.286 0.0764 0.356 -0.715 0.475 validity effect 0.601 0.282 0.068 0.074 0.356 -0.715 0.475 validity effect 0.601 0.282 0.068 0.074 0.356 -0.715 0.475 Planker -0.107 0.115 0.013 -0.118 0.332 0.932 0.351 al 0.107 -0.790 1.004 -0.780 0.185	gap effect 0.017 0.254 0.065 -0.481 0.515 0.067 0.946 validity effect 1.920 0.467 0.218 1.004 2.836 4.110 0.000 benefit -0.204 0.286 0.082 -0.748 0.356 0.075 0.475 validity effect 0.801 0.282 0.082 -0.748 0.356 0.040 Flanker -0.237 0.171 0.029 -0.572 0.097 -1.391 0.164 0.107 0.118 0.332 0.932 0.351 0.164 al 0.107 -0.790 1.004 -0.790 1.024 al 0.121 -0.879 1.120 -0.879 1.224 0.185	gap effect 0.017 0.254 0.065 -0.481 0.515 0.067 0.946 validity effect 1.920 0.467 0.218 1.004 2.836 4.110 0.000 benefit -0.204 0.286 0.028 0.775 0.475 0.475 validity effect 0.601 0.2292 0.085 0.028 1.713 2.066 0.040 Ranker 0.107 0.115 0.013 -0.118 0.332 0.932 0.351 al 0.107 0.115 0.013 -0.118 0.332 0.932 0.351 al 0.121 0.091 0.086 0.299 1.324 0.185 al 0.121 0.991 1.120 -0.879 1.120 -1.00 -0.50 0.00 0.50

Likely due to understandable difficulty in using the same measures for young infants as for older children and adults, we were not able to find any genetic studies of RA in infants younger than 6-months-old (see Figure 8). This is less than ideal because birth to 6-months-old is when RA might show the most development (Atkinson and Braccick, 2012; Colaizzi et al., 2014; Courage et al., 2006; Kannass et al., 2006; Posner et al., 2012; Richards, 2005; Varga et al., 2010). If infants had been included, we might have seen stronger effects of age on RA and been able to determine if they are linear.


Dopamine-related genetic markers

We found no evidence that dopamine-related or non-dopaminerelated genes impacted RA. The pooled effect sizes for both groups are similar prediction intervals for both were wide, suggesting future studies might achieve results anywhere in a relatively large band that spans zero. Many researchers study the effects of genetic polymorphisms on human behavior because the markers influence the availability of neurotransmitters. Dopamine, in particular, is a common biological pathway to behavior named in genetic studies (Blum et al., 2000). In this meta-analysis, dopamine-related genes showed more variance than non-dopamine-related genes. Several studies suggest non-dopamine-related genes also have significant influence on RA. For example, norepinephrine is crucial for maintaining alertness, arousal, and attention and that individuals with ADHD may have lower norepinephrine levels, contributing to difficulties with sustained attention (Beane and Marrocco, 2004). Similarly, acetylcholine plays a significant role in attentional arousal (Beane and Marrocco, 2004; Oberlin et al., 2005). Serotonin also influences attention (Oades and Müller, 1997). Glutamate is an excitatory neurotransmitter involved in various brain functions such as attention (Cid-Jofré et al., 2022; Park et al., 2013). With more studies of genetic influence on RA, researchers may be able to examine the effects of these neurotransmitters individually.

However, fewer studies are published associating or attempting to associate noradrenergic, cholinergic, serotoninergic, and glutamatergic genes to RA. A general university database search for studies on genes predicting RA found acetylcholine as n = 160 and norepinephrine as n = 180 compared to dopamine (n = 483). This may be confirmation bias in the sense that there is a tendency to investigate neurotransmitters which have already been found as significant by other researchers (Bishop, 2020; Radua and Fullana, 2022). Dopamine's role is particularly well-studied in conditions like ADHD.

Limitations

Correct interpretation of meta-analyses is important to avoid invalid generalizations (Aikins et al., 2001; Ramasamy et al., 2008). The biggest caveat to keep in mind is that we can only generalize our results to studies comparable to those in our analysis. This includes studies with the same



mix of samples, outcomes, and predictors, which can be complicated (van Dijk et al., 2024; Wang et al., 2020). In this case, our analysis is complicated by the fact that it cannot point to any specific genetic markers as more important than others. Instead, we considered the biologic effect of each marker (Collins et al., 2003; Otero-Carrasco et al., 2024) by looking at its influence on the availability of dopamine.

Another limitation was the inability to of our team to comprehend all relevant languages. The lack of non-English studies is an issue because it suggests the likelihood that genetic and cultural groups may be missing form inclusion. Including them would have allowed us to access more diverse studies and improve our estimates.

Although all included studies had reasonable quality ratings using the Q-Genie measure (Sohani et al., 2015), 6 of 37 studies were considered under-powered by two raters using the Q-Genie measure. This relates to a single item on Q-Genie and thus did not strongly impact study quality ratings.

Finally, there were concerning aspects of the studies that were not assessed by Q-Genie. For example, 25 of 37 studies did not report ethnicity and none reported socioeconomic status or income, which may sometimes be associated with impaired attention. Six of the studies included some aspect of age besides mean and standard deviation (e.g., including only the standard deviation). Relatedly, we were not able to find any studies with a sample size larger than 336. Given that 21 of the 37 studies were published prior to 2013, which is arguably when the replication crisis became common knowledge (Asendorpf et al., 2013), larger studies reporting on more details would likely be helpful. Future genetic meta-analyses may need alternative means of rating studies that consider factors important to avoiding failure to replicate.

Implications

Our main finding emphasizes that the influence of genes on RA varies by age group. Additionally, some outcome measures show more heterogeneity than others and this should be considered by researchers when choosing outcomes. Similarly, studies testing non dopaminerelated genes had lower heterogeneity than those testing dopaminerelated genes. For future candidate gene studies, we recommend including genes associated with a wider variety of neurotransmitters. Our strongest recommendation is that more complete reporting is needed within studies, including age and ethnicity. We also urge more effort be placed on recruiting and reporting diverse ethnic groups. When conducting a meta-analysis, we advise collaborating with colleagues who understand diverse languages (e.g., Chinese) at the level of academic journal writing. While our findings are interesting, it remains important to study specific neurotransmitters rather than neurotransmitters at a binary level.

Conclusion

In summary, we combined past RA gene association studies to consolidate what we can learn from them. Our method of analysis allowed for better estimates of effect sizes than individual studies. The significant effect sizes we found for children as opposed to adults in how well genes predict RA outcomes could benefit future studies in the development of this foundational cognitive ability. We believe these results are important, in part because RA is foundational to development and higher cognitive processes.

Data availability statement

Publicly available datasets were analyzed in this study. Data were extracted from published articles.

Author contributions

SM: Data curation, Investigation, Project administration, Validation, Writing – original draft, Writing – review & editing. KC:

Conceptualization, Data curation, Investigation, Methodology, Project administration, Validation, Writing – original draft, Writing – review & editing. RL: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Visualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. We thank Brigham Young University for paying research assistant wages.

Acknowledgments

We would like to thank Eliza Broadbent, Amaya Chikuni, Clayton Chudleigh, and Marissa Farmer for their help in finding studies and

References

Aikins, D. E., Hazlett-Stevens, H., and Craske, M. G. (2001). Issues of measurement and mechanism in meta-analyses: comment on Westen and Morrison (2001). J. Consult. Clin. Psychol. 69, 904–907. doi: 10.1037//0022-006x.69.6.904

Andreou, D., Saetre, P., Kähler, A. K., Werge, T., Andreassen, O. A., Agartz, I., et al. (2011). Dystrobrevin-binding protein 1 gene (DTNBP1) variants associated with cerebrospinal fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in healthy volunteers. *Eur. Neuropsychopharmacol.* 21, 700–704. doi: 10.1016/j.euroneuro.2010.12.008

Anguera, J. A., Brandes-Aitken, A. N., Rolle, C. E., Skinner, S. N., Desai, S. S., Bower, J. D., et al. (2016). Characterizing cognitive control abilities in children with 16p11.2 deletion using adaptive "video game" technology: a pilot study. *Transl. Psychiatry* 6, e893, 1–9. doi: 10.1038/tp.2016.178

Anokhin, A. P., van Baal, G. C. M., van Beijsterveldt, C. E. M., de Geus, E. J. C., Grant, J., and Boomsma, D. I. (2001). Genetic correlation between the P300 event-related brain potential and the EEG power spectrum. *Behav. Genet.* 31, 545–554. doi: 10.1023/A:1013341310865

Asendorpf, J. B., Conner, M., De Fruyt, F., De Houwer, J., Denissen, J. J. A., Fiedler, K., et al. (2013). Recommendations for increasing replicability in psychology. *Eur. J. Personal.* 27, 108–119. doi: 10.1002/per.1919

Atkinson, J., and Braccick, O. (2012). Visual attention in the first years: typical development and developmental disorders. *Devolp. Med. Child Neurol.* 54, 589–595. doi: 10.1111/j.1469-8749.2012.04294.x

Axelrod, J., and Tomchick, R. (1958). Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 233, 702–705. doi: 10.1016/S0021-9258(18)64731-3

Bagherzadeh-Azbari, S., Lion, C. J., Stephani, T., Dimigen, O., and Sommer, W. (2023). The impact of emotional facial expressions on reflexive attention depends on the aim of dynamic gaze changes: an ERP study. *Psychophysiology* 60, 1–18. doi: 10.1111/psyp.14202

Beane, M., and Marrocco, R. T. (2004). Norepinephrine and acetylcholine mediation of the components of reflexive attention: implications for attention deficit disorders. *Prog. Neurobiol.* 74, 167–181. doi: 10.1016/j.pneurobio.2004.09.001

Begg, C. B., and Mazumdar, M. (1994). Operating characteristics of a rank correlation test for publication bias. *Biometrics* 50, 1088–1101. doi: 10.2307/2533446

Bellgrove, M. A., Chambers, D. C., Johnson, K. A., Daibhis, A., Daly, M., Hawi, Z., et al. (2007). Dopaminergic genotype biases spatial attention in healthy children. *Mol. Psychiatry* 12, 786–792. doi: 10.1038/sj.mp.4002022

Bellgrove, M. A., Johnson, K. A., Barry, E., Mulligan, A., Hawi, Z., Gill, M., et al. (2009). Dopamine haplotype as a predictor of spatial inattention in children with attention-deficit/hyperactivity disorder. *Arch. Gen. Psychiatry* 66, 1135–1142. doi: 10.1001/archgenpsychiatry.2009.120

Bellgrove, M. A., O'Connell, R. G., and Vance, A. (2008). Genetics of cognitive deficits in ADHD: clues for novel treatment methods. *Expert Reviews Neurotherap* 8, 553–561. doi: 10.1586/14737175.8.4.553

Birkas, E., Horváth, J., Lakatos, K., Nemoda, Z., Sasvari-Szekely, M., Winkler, I., et al. (2006). Association between dopamine D4 receptor (DRD4) gene polymorphisms and novelty-elicited auditory event-related potentials in preschool children. *Brain Res.* 1103, 150–158. doi: 10.1016/j.brainres.2006.03.021

extracting data. We would also like to thank our methodologist, Chongming Yang, for providing feedback on our analytic choices.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Bish, J. P., Chiodo, R., Mattei, V., and Simon, T. J. (2007). Domain specific attentional impairments in children with chromosome 22q112 deletion syndrome. *Brain Cogn.* 64, 265–273. doi: 10.1016/j.bandc.2007.03.007

Bishop, D. V. M. (2020). The psychology of experimental psychologists: overcoming cognitive constraints to improve research: the 47th sir Frederic Bartlett lecture. *Q. J. Exp. Psychol.* 73, 1–19. doi: 10.1177/1747021819886519

Blum, K., Braverman, E. R., Holder, J. M., Lubar, J. F., Monastra, V. J., Miller, D., et al. (2000). Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. *J. Psychoactive Drugs* 32, 1–112. doi: 10.1080/02791072.2000.10736099

Board, N. G. E. (2005). Framework for a fully powered risk engine. *Nat. Genet.* 37:1153. doi: 10.1038/ng1105-1153

Bobb, A. J., Addington, A. M., Sidransky, E., Gornick, M. C., Lerch, J. P., Greenstein, D. K., et al. (2005). Support for association between ADHD and two candidate genes: NET1 and DRD1. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 134B, 67–72. doi: 10.1002/ajmg.b.30142

Boccia, S., De Feo, E., Galli, P., Gianfagna, F., Amore, R., Ricciardi, G., et al. (2010). A systematic review evaluating the methodological aspects of meta-analyses of genetic association studies in cancer research. *Eur. J. Epidemiol.* 25, 765–775. doi: 10.1093/aje/kwm344

Borenstein, M. (2020). Research note: in a meta-analysis, the l^2 index does not tell us how much the effect size varies across studies. *J. Physiother.* 66, 135–139. doi: 10.1016/j.jphys.2020.02.011

Borenstein, M., Hedges, L. E., Higgins, J. P. T., and Rothstein, H. R. (2022). Comprehensive Meta-analysis version 4. Biostat, Inc. Available online at: www.Meta-Analysis.com (Accessed January 04, 2025).

Brodeur, D. A., and Enns, J. T. (1997). Covert visual orienting across the lifespan. *Can. J. Exp. Psychol.* 51, 20–35. doi: 10.1037/1196-1961.51.1.20

Burstein, M. A., Zevin, Z., and Geva, R. (2021). Preterm birth and the development of visual attention during the first 2 years of life a systematic review and meta-analysis. *JAMA Netw. Open* 4:e213687. doi: 10.1001/jamanetworkopen.2021.3687

Chen, J., Lin, M., Hrabovsky, A., Pedrosa, E., Dean, J., Jain, S., et al. (2015). ZNF804A transcriptional networks in differentiating neurons derived from induced pluripotent stem cells of human origin. *PLoS One* 10:e0124597. doi: 10.1371/journal.pone.0124597

Chen, G. Y., Muramatsu, H., Ichihara-Tanaka, K., and Muramatsu, T. (2004). ZEC, a zinc finger protein with novel binding specificity and transcription regulatory activity. *Gene* 340, 71–81. doi: 10.1016/j.gene.2004.06.016

Chernenok, M., Burris, J. L., Owen, E., and Rivera, S. M. (2019). Impaired attention orienting in young children with fragile X syndrome. *Front. Psychol.* 10, 1–8. doi: 10.3389/fpsyg.2019.01567

Chung, W. K., Roberts, T. P. L., Sherr, E. H., Synder, L. G., and Spiro, J. E. (2021). 16p11.2 deletion syndrome. *Curr. Opin. Genet. Dev.* 68, 49–56. doi: 10.1016/j.gde.2021.01.011 Ciabarra, A. M., Sullivan, J. M., Gahn, L. G., Pecht, G., Heinemann, S., and Sevarino, K. A. (1995). Cloning and characterization of chi-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family. *J. Neurosci.* 15, 6498–6508. doi: 10.1523/JNEUROSCI.15-10-06498.1995

Cid-Jofré, V., Moreno, M., Sotomayor-Zárate, R., Cruz, G., and Renard, G. M. (2022). Modafinil administration to preadolescent rat impairs non-selective attention, frontal cortex D2 expression and mesolimbic GABA levels. *Int. J. Mol. Sci.* 23:6602. doi: 10.3390/ijms23126602

Colaizzi, J., Aubuchon-Endsley, N., Grant, S. L., Kennedy, T. S., and Thomas, D. G. (2014). Typical and atypical development of visual attention in 3- to 9-month-old infants. *Infancy* 19, 519–542. doi: 10.1111/infa.12061

Collins, F. S., Green, E. D., Guttmacher, A. E., and Guyer, M. S. (2003). A vision for the future of genomics research. *Nature* 422, 835–847. doi: 10.1038/nature01626

Committee on Standards for Systematic Reviews of Comparative Effectiveness Research (2011) in Finding what works in health care: Standards for systematic reviews. eds. J. Eden, L. Levit, A. Berg and S. Morton (Washington, DC, USA: Institute of Medicine National Academies Press (US)).

Cornish, K. M., Li, L., Kogan, C. S., Jacquemont, S., Turk, J., Dalton, A., et al. (2008). Age-dependent cognitive changes in carriers of the fragile X syndrome. *Cortex* 44, 628–636. doi: 10.1016/j.cortex.2006.11.002

Couette, M., Bachoud-Levi, A.-C., Brugieres, P., Sieroff, E., and Bartolomeo, P. (2008). Orienting of spatial attention in Huntington's disease. *Neuropsychologia* 46, 1391–1400. doi: 10.1016/j.neuropsychologia.2007.12.017

Courage, M. L., Reynolds, G. D., and Richards, J. E. (2006). Infants' attention to patterned stimuli: developmental change from 3 to 12 months of age. *Child Dev.* 77, 680–695. doi: 10.1111/j.1467-8624.2006.00897.x

Dannemiller, J. L. (2004). Variations in birth weight within the normal range are related to visual orienting in infancy for boys but not for girls. *Infant Behav. Dev.* 27, 204–215. doi: 10.1016/j.infbeh.2003.09.003

Das, S., Sasaki, Y. F., Rothe, T., Premkumar, L. S., Takasu, M., Crandall, J. E., et al. (1998). Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. *Nature* 393, 377–381. doi: 10.1038/30748

D'Elia, A., Schiavi, S., Manduca, A., Rava, A., Buzzelli, V., Ascone, F., et al. (2022). FMR1 deletion in rats induces hyperactivity with no changes in striatal dopamine transporter availability. *Sci. Rep.* 12:22535. doi: 10.1038/s41598-022-26986-2

Dong, F., Mao, J., Chen, M., Yoon, J., and Mao, Y. (2021). Schizophrenia risk ZNF804A interacts with its associated proteins to modulate dendritic morphology and synaptic development. *Mol. Brain* 14:12. doi: 10.1186/s13041-021-00729-2

Dunican, D., Pennings, S., and Meehan, R. (2007). "Epigenetic modification of chromatin," in *Genes and common diseases: genetics in modern medicine*. eds. A. Wright and N. Hastie. p. 20–43.

Dye, M. W., and Bavelier, D. (2010). Differential development of visual attention skills in school-age children. Vis. Res. 50, 452–459. doi: 10.1016/j.visres.2009.10.010

Eicher, J. D., and Gruen, J. R. (2015). Language impairment and dyslexia genes influence language skills in children with autism spectrum disorders. *Autism Res.* 8, 229–234. doi: 10.1002/aur.1436

Enns, J. T. (1990). "Relations between components of attention" in The development of attention: Research and theory. ed. J. T. Enns (Amsterdam: North-Holland), 139–158.

Eriksen, B. A., and Eriksen, C. W. (1974). Effects of noise letters upon the identification of a target letter in a nonsearch task. *Percept. Psychophys.* 16, 143–149. doi: 10.3758/BF03203267

Eriksen, C. W., and Schultz, D. W. (1979). Information processing in visual search: a continuous flow conception and experimental results. *Percept. Psychophys.* 25, 249–263. doi: 10.3758/BF03198804

Espeseth, T., Endestad, T., Rootwelt, H., and Reinvang, I. (2007). Nicotine receptor gene CHRNA4 modulates early event-related potentials in auditory and visual oddball target detection tasks. *Neuroscience* 147,974–985. doi: 10.1016/j.neuroscience.2007.04.027

Fan, J., Fossella, J., Sommer, T., Wu, Y., and Posner, M. I. (2003). Mapping the genetic variation of executive attention onto brain activity. *Proc. Natl. Acad. Sci. USA* 100, 7406–7411. doi: 10.1073/pnas.0732088100

Feng, Q., and Zhang, X. (2014). Eye gaze triggers reflexive attention shifts: evidence from lateralised ERPs. *Brain Res.* 1589, 37–44. doi: 10.1016/j.brainres.2014.09.029

Ferré, S., Belcher, A. M., Bonaventura, J., Quiroz, C., Sánchez-Soto, M., Casadó-Anguera, V., et al. (2022). Functional and pharmacological role of the dopamine D 4 receptor and its polymorphic variants. *Front. Endocrinol.* 13, 1–14. doi: 10.3389/fendo.2022.1014678

Freimer, N., and Sabatti, C. (2003). The human phenome project. *Nat. Genet.* 34, 15–21. doi: 10.1038/ng0503-15

Gallinat, J., Bajbouj, M., Sander, T., Schlattmann, P., Xu, K., Ferro, E. F., et al. (2003). Association of the G1947A COMT (Val(108/158)met) gene polymorphism with prefrontal P300 during information processing. *Biol. Psychiatry* 54, 40–48. doi: 10.1016/s0006-3223(02)01973-x

Gallinat, J., Götz, T., Kalus, P., Bajbouj, M., Sander, T., and Winterer, G. (2007). Genetic variations of the NR3A subunit of the NMDA receptor modulate prefrontal cerebral activity in humans. J. Cogn. Neurosci. 19, 59-68. doi: 10.1162/jocn.2007.19.1.59

Gao, L., Chen, J., Gu, L., Shu, H., Wang, Z., Liu, D., et al. (2018). Effects of gender and apolipoprotein E on novelty MMN and P3a in healthy elderly and amnestic mild cognitive impairment. *Front. Aging Neurosci.* 10, 1–9. doi: 10.3389/fnagi.2018.00256

Giros, B., Godinot, N., Zheng, K., Han, H., Yang-Feng, T., and Caron, M. G. (1992). Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. *Mol. Pharmacol.* 42, 383–390. doi: 10.1016/S0026-895X(25)08925-4

Godfrey, K. E., Gardner, A. C., Kwon, S., Chea, W., and Muthukumaraswamy, S. D. (2018). Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: a systematic review and meta-analysis. *J. Psychiatr. Res.* 105, 33–44. doi: 10.1016/j.jpsychires.2018.08.015

Greenwood, P. M., Lambert, C., Sunderland, T., and Parasuraman, R. (2005). Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: results from the National Institute of Mental Health's BIOCARD study. *Neuropsychology* 19, 199–211. doi: 10.1037/0894-4105.19.2.199

Guna, A., Butcher, N. J., and Bassett, A. S. (2015). Comparative mapping of the 22q11.2 deletion region and the potential of simple model organisms. *J. Neurodev. Disord.* 7:18. doi: 10.1186/s11689-015-9113-x

Gwet, K. L. (2014). Handbook of inter-rater reliability: The definitive guide to measuring the extent of agreement among raters. Gaithersburg, MD, USA: Advanced Analytics, LLC.

Gwinn, M., Ioannidis, J. P., Little, J., and Khoury, M. J. (2014). Editorial: updated guidance on human genome epidemiology (HuGE) reviews and meta-analyses of genetic associations. *Am. J. Epidemiol.* 180, 559–561. doi: 10.1093/aje/kwu196

Hanson, E., Nasir, R. H., Fong, A., Lian, A., Hundley, R., Shen, Y., et al. (2010). Cognitive and behavioral characterization of 16p112 deletion syndrome. *J. Dev. Behav. Pediatr.* 31, 649–657. doi: 10.1097/DBP.0b013e3181ea50ed

Harman, C., Posner, M. I., Rothbart, M. K., and Thomas-Thrapp, L. (1994). Development of orienting to locations and objects in human infants. *Can. J. Exp. Psychol.* 48, 301–318. doi: 10.1037/1196-1961.48.2.301

Hawks, Z. W., and Constantino, J. N. (2020). Neuropsychiatric 'comorbidity' as causal influence in autism. *J. Am. Acad. Child Adolesc. Psychiatry* 59, 229–235. doi: 10.1016/j.jaac.2019.07.008

Hedges, L. V., and Vevea, J. L. (1998). Fixed and random-effects models in metaanalysis. *Psychol. Methods* 3, 486–504. doi: 10.1037/1082-989X.3.4.486

Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., et al. (2019). Cochrane handbook for systematic reviews of interventions. Oxford, UK: Wiley.

Higgins, J. P. T., and Thompson, S. G. (2002). Quantifying heterogeneity in a metaanalysis. *Stat. Med.* 21, 1539–1558. doi: 10.1002/sim.1186

Higgins, J. P., Thompson, S. G., Deeks, J. J., and Altman, D. G. (2003). Measuring inconsistency in meta-analyses. Br. Med. J. 327, 557–560. doi: 10.1136/bmj.327.7414.557

Higgins, J. P., Thompson, S. G., and Spiegelhalter, D. J. (2009). A re-evaluation of random-effects meta-analysis. *J. Royal Statistical Society Series A*. 172, 137–159. doi: 10.1111/j.1467-985X.2008.00552.x

Holmboe, K., Nemoda, Z., Fearon, R. M. P., Csibra, G., Sasvari-Szekely, M., and Johnson, M. H. (2010). Polymorphisms in dopamine system genes are associated with individual differences in attention in infancy. *Dev. Psychol.* 46, 404–416. doi: 10.1037/a0018180

Hunter, J., Rivero-Arias, O., Angelov, A., Kim, E., Fotheringham, I., and Leal, J. (2014). Epidemiology of fragile X syndrome: a systematic review and meta-analysis. *Am. J. Med. Genet. A* 164, 1648–1658. doi: 10.1002/ajmg.a.36511

IntHout, J., Ioannidis, J. A. P., Rovers, M. M., and Goeman, J. J. (2016). Plea for routinely presenting prediction intervals in meta-analysis. *Br. Med. J. Open* 6:e010247. doi: 10.1136/bmjopen-2015-010247

Jones, W., and Kiln, A. (2013). Attention to eyes is present but in decline in 2-6-monthold infants later diagnosed with autism. *Nature* 504, 427-431. doi: 10.1038/nature12715

Kannass, K. N., Oakes, L. M., and Shaddy, D. J. (2006). A longitudinal investigation of the development of attention and distractibility. *J. Cogn. Dev.* 7, 381–409. doi: 10.1207/s15327647jcd0703_8

Kumar, R. A., Marshall, C. R., Badner, J. A., Babatz, T. D., Mukamel, Z., Aldinger, K. A., et al. (2009). Association and mutation analyses of 16p11.2 autism candidate genes. *PLoS One* 4:e4582. doi: 10.1371/journal.pone.0004582

Lehmann, M., Neumann, C., Wasserthal, S., Delis, A., Schultz, J., Hurlemann, R., et al. (2022). Ketamine increases fronto-posterior functional connectivity during metaperceptual confidence ratings. *Behav. Brain Res.* 430:113925. doi: 10.1016/j.bbr.2022.113925

Li, A., and Meyre, D. (2013). Challenges in reproducibility of genetic association studies: lessons learned from the obesity field. *Int. J. Obes.* 37, 559–567. doi: 10.1038/ijo.2012.82

Li, D., Sham, P. C., Owen, M. J., and He, L. (2006a). Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). *Hum. Mol. Genet.* 15, 2276–2284. doi: 10.1093/hmg/ddl152

Li, J., Wang, Y., Zhou, R., Wang, B., Zhang, H., Yang, L., et al. (2006b). Association of attention-deficit/hyperactivity disorder with serotonin 4 receptor gene polymorphisms in Han Chinese subjects. *Neurosci. Lett.* 401, 6–9. doi: 10.1016/j.neulet.2006.02.053

Linderkamp, O., and Linderkamp-Skoruppa, D. B. (2020). "Prenatal structural brain development: genetic and environmental determinants" in Handbook of prenatal and perinatal psychology. eds. L. J. Klaus Evertz and R. Linder (Cham, Switzerland: Springer), 1–18.

Little, T. D., Bovaird, J. A., and Card, N. A. (2012). Modeling contextual effects in longitudinal studies. New York, NY, USA: Routledge.

Little, J., Higgins, J. P., Ioannidis, J. P., Moher, D., Gagnon, F., von Elm, E., et al. (2009). STrengthening the REporting of genetic association studies (STREGA)--an extension of the STROBE statement. *Genet. Epidemiol.* 33, 581–598. doi: 10.1002/gepi.20410

Lowe, N., Kirley, A., Mullins, C., Fitzgerald, M., Gill, M., and Hawi, Z. (2004). Multiple marker analysis at the promoter region of the DRD4 gene and ADHD: evidence of linkage and association with the SNP –616. *Am. J. Med. Genet.* 131B, 33–37. doi: 10.1002/ajmg.b.30071

Luikenhuis, S., Giacometti, E., Beard, C. F., and Jaenisch, R. (2004). Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. *Proc. Natl. Acad. Sci. USA* 101, 6033–6038. doi: 10.1073/pnas.0401626101

Lundwall, R. A., and Dannemiller, J. L. (2015). Genetic contributions to attentional response time slopes across repeated trials. *BMC Neurosci.* 16:66. doi: 10.1186/ s12868-015-0201-3

Lundwall, R. A., Dannemiller, J. L., and Goldsmith, H. H. (2017). Genetic associations with reflexive visual attention in infancy and childhood. *Dev. Sci.* 20:e12371. doi: 10.1111/desc.12371

Lundwall, R. A., Guo, D. C., and Dannemiller, J. L. (2012). Exogenous visual orienting is associated with specific neurotransmitter genetic markers: a population-based genetic association study. *PLoS One* 7:e30731. doi: 10.1371/journal.pone.0030731

Lundwall, R. A., and Rasmussen, C. (2016). MAOA influences the trajectory of attentional development. Front. Hum. Neurosci. 10, 1–15. doi: 10.3389/fnhum.2016.00424

Lundwall, R. A., Woodruff, J., and Tolboe, S. P. (2018). RT slowing to valid cues on a reflexive attention task in children. *Front. Psychol.* 9:1324. doi: 10.3389/fpsyg.2018.01324

Lyytinen, H., Naatanen, R., Sokolov, E. N., and Spinks, J. (2002). The orienting response in information processing. Mahwah, New Jersey, USA: Taylor & Francis.

Mammen, J. R., and Arcoleo, K. (2019). Understanding the genetics of asthma and implications for clinical practice. *J. Amer. Assoc. Nurse Practice* 31, 384–387. doi: 10.1097/JXX.00000000000246

Mannarelli, D., Pauletti, C., Accinni, T., Carlone, L., Frascarelli, M., Lattanzi, G. M., et al. (2018). Attentional functioning in individuals with 22q11 deletion syndrome: insight from ERPs. *J. Neural Transm.* 125, 1043–1052. doi: 10.1007/s00702-018-1873-5

Männik, K., Mägi, R., Macé, A., Cole, B., Guyatt, A. L., Shihab, H. A., et al. (2015). Copy number variations and cognitive phenotypes in unselected populations. *JAMA J. Am. Med. Assoc.* 313, 2044–2054. doi: 10.1001/jama.2015.4845

Marco-Pallarés, J., Nager, W., Krämer, U. M., Cunillera, T., Càmara, E., Cucurell, D., et al. (2010). Neurophysiological markers of novelty processing are modulated by COMT and DRD4 genotypes. *NeuroImage* 53, 962–969. doi: 10.1016/j.neuroimage.2010.02.012

Markant, J., Cicchetti, D., Hetzel, S., and Thomas, K. M. (2014). Relating dopaminergic and cholinergic polymorphisms to spatial attention in infancy. *Dev. Psychol.* 50, 360–369. doi: 10.1037/a0033172

Maurage, P., Heeren, A., Lahaye, M., Jeanjean, A., Guettat, L., Verellen-Dumoulin, C., et al. (2017). Attentional impairments in Huntington's disease: a specific deficit for the executive conflict. *Neuropsychology* 31, 424–436. doi: 10.1037/neu0000321

McCauley, J. L., Olson, L. M., Dowd, M., Amin, T., Steele, A., Blakely, R. D., et al. (2004). Linkage and association analysis at the serotonin transporter (SLC6A4) locus in a rigid-compulsive subset of autism. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 127B, 104–112. doi: 10.1002/ajmg.b.20151

McKinnon, L. A., and Nathanson, N. M. (1995). Tissue-specific regulation of muscarinic acetylcholine receptor expression during embryonic development. *J. Biol. Chem.* 270, 20636–20642. doi: 10.1074/jbc.270.35.20636

Meller, T., Schmitt, S., Stein, F., Brosch, K., Mosebach, J., Yüksel, D., et al. (2019). Associations of schizophrenia risk genes ZNF804A and CACNA1C with schizotypy and modulation of attention in healthy subjects. *Schizophr. Res.* 208, 67–75. doi: 10.1016/j.schres.2019.04.018

Minelli, C., Thompson, J. R., Abrams, K. R., Thakkinstian, A., and Attia, J. (2009). The quality of meta-analyses of genetic association studies: a review with recommendations. *Am. J. Epidemiol.* 170, 1333–1343. doi: 10.1093/aje/kwp350

Nasir, J., Floresco, S. B., O'Kusky, J. R., Diewert, V. M., Richman, J. M., Zeisler, J., et al. (1995). Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. *Cell* 81, 811–823. doi: 10.1016/0092-8674(95)90542-1

Newman, D. P., Cummins, T. D. R., Tong, J. S., Johnson, B. P., Pickering, H., Fanning, P., et al. (2014). Dopamine transporter genotype is associated with a lateralized resistance to distraction during attention selection. *J. Neurosci.* 34, 15743–15750. doi: 10.1523/JNEUROSCI.2327-14.2014

Nicodemus, K. K., Hargreaves, A., Morris, D., Anney, R., Gill, M., Corvin, A., et al. (2014). Variability in working memory performance explained by epistasis vs polygenic

scores in the ZNF804A pathway. JAMA Psychiatry 71, 778-785. doi: 10.1001/jamapsychiatry.2014.528

Nikolova, Y. S., Ferrell, R. E., Manuck, S. B., and Hariri, A. R. (2011). Multilocus genetic profile for dopamine signaling predicts ventral striatum reactivity. *Neuropsychopharmacology* 36, 1940–1947. doi: 10.1038/npp.2011.82

Oades, R. D., and Müller, B. (1997). The development of conditioned blocking and monoamine metabolism in children with attention-deficit-hyperactivity disorder or complex tics and healthy controls: an exploratory analysis. *Behav. Brain Res.* 88, 95–102. doi: 10.1016/S0166-4328(97)02306-1

Oberlin, B. G., Alford, J. L., and Marrocco, R. T. (2005). Normal attention orienting but abnormal stimulus alerting and conflict effect in combined subtype of ADHD. *Behav. Brain Res.* 165, 1–11. doi: 10.1016/j.bbr.2005.06.041

O'Donoghue, T., Morris, D. W., Fahey, C., Da Costa, A., Moore, S., Cummings, E., et al. (2014). Effects of ZNF804A on auditory P300 response in schizophrenia. *Transl. Psychiatry* 4:e345. doi: 10.1038/tp.2013.115

Oriá, R. B., Patrick, P. D., Oriá, M. O., Lorntz, B., Thompson, M. R., Azevedo, O. G., et al. (2010). ApoE polymorphisms and diarrheal outcomes in Brazilian shanty town children. *Braz. J. Med. Biol. Res.* 43, 249–256. doi: 10.1590/s0100-879x2010007500003

Ortega-Mora, I. E., Caballero-Sánchez, U., Román-López, T. V., Rosas-Escobar, C. B., Méndez-Díaz, M., Prospéro-García, O. E., et al. (2021). The alerting and orienting systems of attention are modified by cannabis dependence. *J. Int. Neuropsychol. Soc.* 27, 520–532. doi: 10.1017/S1355617721000369

Otero-Carrasco, B., Carro, E. U., Prieto-Santamaría, L., Uzquiano, M. D., Hernández, J. P. C.-V., and Rodríguez-González, A. (2024). Identifying patterns to uncover the importance of biological pathways on known drug repurposing scenarios. *BMC Genomics* 25:43. doi: 10.1186/s12864-023-09913-1

Ouyang, X., Pan, Y., Chen, X., Wu, G., Cheng, Y., Tan, W., et al. (2023). Cortical morphological heterogeneity of schizophrenia and its relationship with glutamatergic receptor variations. *Eur. Psychiatry* 66, e38, 1–12. doi: 10.1192/j.eurpsy.2023.2408

Owen, E. R. (2015). An investigation of the development of selective visual attention: Studies in fragile x syndrome and typical infants (publication number 3737022) University of California, Davis]. ProQuest Dissertations & Theses Global.

Page, M. J., Sterne, J. A. C., Higgins, J. P. T., and Egger, M. (2021). Investigating and dealing with publication bias and other reporting biases in meta-analyses of health research: a review. *Res. Synth. Methods* 12, 248–259. doi: 10.1002/jrsm.1468

Papassotiropoulos, A., and de Quervain, D. J. F. (2011). Genetics of human episodic memory: dealing with complexity. *Trends Cogn. Sci.* 15, 381–387. doi: 10.1016/j.tics.2011.07.005

Parasuraman, R., Greenwood, P. M., Kumar, R., and Fossella, J. (2005). Beyond heritability neurotransmitter genes differentially modulate visuospatial attention and working memory. *Psychol. Sci.* 16, 200–207. doi: 10.1111/j.0956-7976.2005.00804.x

Parasuraman, R., Greenwood, P. M., and Sunderland, T. (2002). The apolipoprotein E gene, attention, and brain function. *Neuropsychology* 16, 254–274. doi: 10.1037/0894-4105.16.2.254

Park, S., Sun-Woo, J., Boong-Nyun, K., Soo-Churl, C., Min-Sup, S., Jae-Won, K., et al. (2013). Association between the GRM7 rs3792452 polymorphism and attention deficit hyperacitiveity disorder in a Korean sample. *Behav. Brain Funct.* 9, 1–8. doi: 10.1186/1744-9081-9-1

Phelps, E. A., Ling, S., and Carrasco, M. (2006). Emotion facilitates perception and potentiates the perceptual benefits of attention. *Psychol. Sci.* 17, 292–299. doi: 10.1111/j.1467-9280.2006.01701.x

Plude, D. J., Enns, J. T., and Brodeur, D. (1994). The development of selective attention: a life-span overview. *Acta Psychol.* 86, 227–272. doi: 10.1016/0001-6918(94)90004-3

Poirier, J. (1996). Apolipoprotein E in the brain and its role in Alzheimer's disease. J. Psychiatry Neurosci. 88, 95–102

Portmann, T., Yang, M., Mao, R., Panagiotakos, G., Ellegood, J., Dolen, G., et al. (2014). Behavioral abnormalities and circuit defects in the basal ganglia of a mouse model of 16p11.2 deletion syndrome. *Cell Rep.* 7, 1077–1092. doi: 10.1016/j.celrep.2014.03.036

Posner, M. I. (1980). Orienting of attention. Q. J. Exp. Psychol. 32, 3-25. doi: 10.1080/00335558008248231

Posner, M. I., Rothbart, M. K., Sheese, B. E., and Voelker, P. (2012). Control networks and neuromodulators of early development. *Dev. Psychol.* 48, 827–835. doi: 10.1037/a0025530

Pozuelos, J. P., Paz-Alonso, P. M., Castillo, A., Fuentes, L. J., and Rueda, M. R. (2014). Development of attention networks and their interactions in childhood. *Dev. Psychol.* 50, 2405–2415. doi: 10.1037/a0037469

Qiu, Z., and Cheng, J. (2010). The role of calcium-dependent gene expression in autism spectrum disorders: lessons from MeCP2, Ube3a and beyond. *Neurosignals* 18, 72–81. doi: 10.1159/000320970

Quan, J., Ong, M.-L., Bureau, J.-F., Sim, L. W., Sanmugam, S., Malik, A. B. A., et al. (2017). The influence of CHRNA4, COMT, and maternal sensitivity on orienting and executive attention in 6-month-old infants. *Brain Cogn.* 116, 17–28. doi: 10.1016/j.bandc.2017.05.002

Quintero, A. I., Beaton, E. A., Harvey, D. J., Ross, J. L., and Simon, T. J. (2014). Common and specific impairments in attention functioning in girls with chromosome 22q11. 2 deletion, fragile X or turner syndromes. *J. Neurodev. Disord.* 6:5. doi: 10.1186/1866-1955-6-5

Radua, J., and Fullana, M. A. (2022). The amygdala and the nine circles of scientific hell-confirmation bias in the brain correlates of psychopathy. *Neurosci. Biobehav. Rev.* 143:104951. doi: 10.1016/j.neubiorev.2022.104951

Ramasamy, A., Mondry, A., Holmes, C. C., and Altman, D. G. (2008). Key issues in conducting a meta-analysis of gene expression microarray datasets. *PLoS Med.* 5:e184. doi: 10.1371/journal.pmed.0050184

Reinvang, I., Espeseth, T., and Gjerstad, L. (2005). Cognitive ERPs are related to ApoE allelic variation in mildly cognitively impaired patients. *Neurosci. Lett.* 382, 346–351. doi: 10.1016/j.neulet.2005.03.024

Reith, M. E. A., Kortagere, S., Wiers, C. E., Sun, H., Kurian, M. A., Galli, A., et al. (2022). The dopamine transporter gene SLC6A3: multidisease risks. *Mol. Psychiatry* 27, 1031–1046. doi: 10.1038/s41380-021-01341-5

Reuter, M., Ott, U., Vaitl, D., and Hennig, J. (2007). Impaired executive control is associated with a variation in the promoter region of the tryptophan hydroxylase 2 gene. *J. Cogn. Neurosci.* 19, 401–408. doi: 10.1162/jocn.2007.19.3.401

Richards, J. E. (2005). "Development of covert orienting in young infants," in *Neurobiology attention*. eds. L. Itti, G. Rees, and J. K. Tsotsos (New York, NY, USA: Elsevier), 82–88).

Richards, J. E., and Hunter, S. K. (2002). Testing neural models of the development of infant visual attention. *Dev. Psychobiol.* 40, 226–236. doi: 10.1002/dev.10029

Rommelse, N. N. J. (2008). Endophenotypes in the genetic research of ADHD over the last decade: have they lived up to their expectations? *Expert. Rev. Neurother.* 8, 1425–1429. doi: 10.1586/14737175.8.10.1425

Rose, S. A., Wass, S., Jankowski, J. J., Feldman, J. F., and Djukic, A. (2019). Attentional shifting and disengagement in Rett syndrome. *Neuropsychology* 33, 335–342. doi: 10.1037/neu0000515

Ross-Sheehy, S., Schneegans, S., and Spencer, J. P. (2015). The infant orienting with attention task: assessing the neural basis of spatial attention in infancy. *Infancy* 20, 467–506. doi: 10.1111/infa.12087

Rothbart, M. K., Sheese, B. E., Rueda, M. R., and Posner, M. I. (2011). Developing mechanisms of self-regulation in early life. *Emot. Rev.* 3, 207–213. doi: 10.1177/1754073910387943

Ruiz-Contreras, A. E., Carrillo-Sánchez, K., Ortega-Mora, I., Barrera-Tlapa, M. A., Román-López, T. V., Rosas-Escobar, C. B., et al. (2014). Performance in working memory and attentional control is associated with the rs2180619 SNP in the CNR1 gene. *Genes Brain Behav.* 13, 173–178. doi: 10.1111/gbb.12097

Ruiz-Contreras, A. E., Román-López, T. V., Caballero-Sánchez, U., Rosas-Escobar, C. B., Ortega-Mora, E. I., Barrera-Tlapa, M. A., et al. (2017). Because difficulty is not the same for everyone: the impact of complexity in working memory is associated with cannabinoid 1 receptor genetic variation in young adults. *Memory* 25, 335–343. doi: 10.1080/09658211.2016.1172642

Saez, I., Set, E., and Hsu, M. (2014). From genes to behavior: placing cognitive models in the context of biological pathways. *Front. Neurosci.* 8, 1–10. doi: 10.3389/fnins.2014.00336

Schneider, M., Debbané, M., Bassett, A. S., Chow, E. W. C., Fung, W. L. A., van den Bree, M. B. M., et al. (2014). Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the international consortium on brain and behavior in 22q11.2 deletion syndrome. *Am. J. Psychiatry* 171, 627–639. doi: 10.1176/appi.ajp.2013.13070864

Schneider, K. K., Schote, A. B., Meyer, J., Markett, S., Reuter, M., and Frings, C. (2015). Individual response speed is modulated by variants of the gene encoding the alpha 4 sub-unit of the nicotinic acetylcholine receptor (CHRNA4). *Behav. Brain Res.* 284, 11–18. doi: 10.1016/j.bbr.2015.01.041

Schulz, S., Arning, L., Pinnow, M., Epplen, J. T., and Beste, C. (2012). N-methyl-Daspartate receptor 2B subunit (GRIN2B) gene variation is associated with alerting, but not with orienting and conflicting in the attention network test. *Neuropharmacology* 63, 259–265. doi: 10.1016/j.neuropharm.2012.02.024

Sechenov, I. M. (1863/1965). "Involuntary movements," in *Reflexes of thebrain*. ed. S. Belsky (Cambridge, MA, USA: MIT Press), 1-42.

Shah, A. A., Amjad, M., Hassan, J.-U., Ullah, A., Mahmood, A., Deng, H., et al. (2022). Molecular insights into the role of pathogenic nsSNPs in GRIN2B gene provoking neurodevelopmental disorders. *Genes* 13:1332. doi: 10.3390/genes13081332

Shiow, L. R., Paris, K., Akana, M. C., Cyster, J. G., Sorensen, R. U., and Puck, J. M. (2009). Severe combined immunodeficiency (SCID) and attention deficit hyperactivity disorder (ADHD) associated with a Coronin-1A mutation and a chromosome 16p11. 2 deletion. *Clin. Immunol.* 131, 24–30. doi: 10.1016/j.clim.2008.11.002

Simon, T. J., Bearden, C. E., Mc-Ginn, D. M., and Zackai, E. (2005). Visuospatial and numerical cognitive deficits in children with chromosome 22Q112 deletion syndrome. *Cortex* 41, 145–155. doi: 10.1016/S0010-9452(08)70889-X

Smith, S. E., and Chatterjee, A. (2008). Visuospatial attention in children. Arch. Neurol. 65, 1284–1288. doi: 10.1001/archneur.65.10.1284

Sobin, C., Kiley-Brabeck, K., Daniels, S., Blundell, M., Anyane-Yeboa, K., and Karayiorgou, M. (2004). Networks of attention in children with the 22q11 deletion syndrome. *Dev. Neuropsychol.* 26, 611–626. doi: 10.1207/s15326942dn2602_5

Sohani, Z. N., Meyre, D., de Souza, R. J., Joseph, P. G., Gandhi, M., Dennis, B. B., et al. (2015). Assessing the quality of published genetic association studies in meta-analyses: the quality of genetic studies (Q-genie) tool. *BMC Genet.* 16, 1–8. doi: 10.1186/s12863-015-0211-2

Sokolov, E. N. (1963). Higher nervous functions: the orienting reflex. Annu. Rev. Physiol. 25, 545–580. doi: 10.1146/annurev.ph.25.030163.002553

Sokolov, E. N. (1966). "Orienting reflex as information regulator," in *Compete works Vol. 3*. ed I. P. Pavlov (Moscow: Publishers of the USSR Academy of Scientists), 334–360.

Stadelmann, A. M., Juckel, G., Arning, L., Gallinat, J., Epplen, J. T., and Roser, P. (2011). Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential. *Neurosci. Lett.* 496, 60–64. doi: 10.1016/j.neulet.2011.04.003

Starr, J. M., Fox, H., Harris, S. E., Deary, I. J., and Whalley, L. J. (2007). COMT genotype and cognitive ability: a longitudinal aging study. *Neurosci. Lett.* 421, 57–61. doi: 10.1016/j.neulet.2007.05.023

Sucher, N. J., Akbarian, S., Chi, C. L., Leclerc, C. L., Awobuluyi, M., Deitcher, D. L., et al. (1995). Developmental and regional expression pattern of a novel NMDA receptorlike subunit (NMDAR-L) in the rodent brain. *J. Neurosci.* 15, 6509–6520. doi: 10.1523/JNEUROSCI.15-10-06509.1995

Takata, A., Iwayama, Y., Fukuo, Y., Ikeda, M., Okochi, T., Maekawa, M., et al. (2013). A population-specific uncommon variant in GRIN3A associated with schizophrenia. *Biol. Psychiatry* 73, 532–539. doi: 10.1016/j.biopsych.2012.10.024

Tang, H., Tang, Y., Zeng, T., and Chen, Z. (2020). Gene expression analysis reveals the tipping points during infant brain development for human and chimpanzee. *BMC Genomics* 21:74. doi: 10.1186/s12864-020-6465-8

Tassone, F., Iong, K. P., Tong, T.-H., Lo, J., Gane, L. W., Berry-Kravis, E., et al. (2012). FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. *Genome Med.* 4:100. doi: 10.1186/gm401

Thimm, M., Kircher, T., Kellermann, T., Markov, V., Krach, S., Jansen, A., et al. (2011). Effects of a CACNA1C genotype on attention networks in healthy individuals. *Psychol. Med.* 41, 1551–1561. doi: 10.1017/S0033291710002217

Thimm, M., Krug, A., Kellermann, T., Markov, V., Krach, S., Jansen, A., et al. (2010). The effects of a DTNBP1 gene variant on attention networks: an fMRI study. *Behav. Brain Funct.* 6, 54–62. doi: 10.1186/1744-9081-6-54

Thompson, J. R., Attia, J., and Minelli, C. (2011). The meta-analysis of genome-wide association studies. *Brief. Bioinform.* 12, 259–269. doi: 10.1093/bib/bbr020

Tsai, T.-T., Lasker, A., and Zee, D. S. (1995). Visual attention in Huntington's disease: the effect of cueing on saccade latencies and manual reaction times. *Neuropsychologia* 33, 1617–1626. doi: 10.1016/0028-3932(95)00094-1

Tye, C., McLoughlin, G., Kuntsi, J., and Asherson, P. (2011). Electrophysiological markers of genetic risk for attention deficit hyperactivity disorder. *Expert Rev. Mol. Med.* 13:e9. doi: 10.1017/S1462399411001797

Van der Molen, M. J. W., Van der Molen, M. W., Ridderinkhof, K. R., Hamel, B. C. J., Curfs, L. M. G., and Ramakers, G. J. A. (2012). Auditory and visual cortical activity during selective attention in fragile X syndrome: a cascade of processing deficiencies. *Clin. Neurophysiol.* 123, 720–729. doi: 10.1016/j.clinph.2011.08.023

van Dijk, A., AlMoghrabi, N., and Leijten, P. (2024). One research question, two metaanalyses, three conclusions: commentary on "a systematic review with meta-analysis of cognitive Bias modification interventions for anger and aggression". *Behav. Res. Ther.* 173:104475. doi: 10.1016/j.brat.2024.104475

van Exel, E., Koopman, J. J. E., Bodegom, D. V., Meij, J. J., Knijff, P., Ziem, J. B., et al. (2017). Effect of APOE ɛ4 allele on survival and fertility in an adverse environment. *PLoS One* 12:e0179497. doi: 10.1371/journal.pone.0179497

van Hooijdonk, C. F. M., Tse, D. H. Y., Roosenschoon, J., Ceccarini, J., Booij, J., van Amelsvoort, T. A. M. J., et al. (2022). The relationships between dopaminergic, glutamatergic, and cognitive functioning in 22q11.2 deletion syndrome: across-sectional, multimodal 1 h-mrs and 18 f-fallypride PET study. *Genes* 13:1672. doi: 10.3390/genes13091672

Varga, K. F. J. E., Kapa, L. L., and Dengler, M. J. (2010). Developmental changes in inhibition of return from 3 to 6 months of age. *Infant Behav. Dev.* 33, 245–249. doi: 10.1016/j.infbeh.2009.12.011

Verkerk, A. J., Pieretti, M., Sutcliffe, J. S., Fu, Y. H., Kuhl, D. P., Pizzuti, A., et al. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. *Cell* 65, 905–914. doi: 10.1016/0092-8674(91)90397-h

Vevea, J. L., and Woods, C. M. (2005). Publication bias in research synthesis: sensitivity analysis using a priori weight functions. *Psychol. Methods* 10, 428–443. doi: 10.1037/1082-989X.10.4.428

Voronin, L. G., and Sokolov, E. N. (1960). Cortical mechanisms of the orienting reflex and its relation to the conditioned reflex. *Electroencephalogr. Clin. Neurophysiol.* 12, 335–346.

Wallis, D., Mauricio, A.-B., Jain, M., Castellanos, F. X., Palacio, J. D., Pineda, D., et al. (2009). Polymorphisms in the neural nicotinic acetylcholine receptor alpha4 subunit (CHRNA4) are associated with ADHD in a genetic isolate. *Attention Deficit Hyperactivity Disorders* 1, 19–24. doi: 10.1007/s12402-009-0003-5

Wang, J., Braskie, M. N., Hafzalla, G. W., Faskowitz, J., McMahon, K. L., de Zubicaray, G. I., et al. (2017). Relationship of a common OXTR gene variant to brain structure and default mode network function in healthy humans. *NeuroImage* 147, 500–506. doi: 10.1016/j.neuroimage.2016.12.062

Wang, Y., Lu, Q., Shi, J., Bao, Y., and Lu, L. (2020). Comment on: 'Sleep in the anxietyrelated disorders: a meta-analysis of subjective and objective research'. *Sleep Med. Rev.* 52:101316. doi: 10.1016/j.smrv.2020.101316

Waszak, F., Li, S. C., and Hommel, B. (2010). The development of attentional networks: cross-sectional findings from a life span sample. *Dev. Psychol.* 46, 337–349. doi: 10.1037/a0018541

Weiss, L. A., Shen, Y., Korn, J. M., Arking, D. E., Miller, D. T., Fossdal, R., et al. (2008). Association between microdeletion and microduplication at 16p11.2 and autism. *N. Engl. J. Med.* 358, 667–675. doi: 10.1056/NEJMoa075974

Winterer, G. M., Musso, F., Konrad, A., Vucurevic, G., Stoeter, P., Sander, T., et al. (2007). Association of attentional network function with exon 5 variations of the CHRNA4 gene. *Hum. Mol. Genet.* 16, 2165–2174. doi: 10.1093/hmg/ddm168

Wood, T. J., Humphrey-Muro, S. M., and Norman, G. R. (2006). Standard setting in a small scale OSCE: a comparison of the modified borderline-group method and the

borderline regression method. Adv. Health Sci. Educ. 11, 115-122. doi: 10.1007/s10459-005-7853-1

Wright, R. O., Hu, H., Silverman, E. K., Tsaih, S. W., Schwartz, J., Bellinger, D., et al. (2003). Apolipoprotein E genotype predicts 24-month bayle y scales infant development score. *Pediatr. Res.* 54, 819–825. doi: 10.1203/01.PDR.0000090927. 53818.DE

Yenkoyan, K., Grigoryan, A., Fereshetyan, K., and Yepremyan, D. (2017). Advances in understanding the pathophysiology of autism spectrum disorders. *Behav. Brain Res.* 331, 92–101. doi: 10.1016/j.bbr.2017.04.038

Zareyan, S., Zhang, H., Wang, J., Song, W., Hampson, E., Abbott, D., et al. (2021). First demonstration of double dissociation between COMT-Met158 and COMT-Val158 cognitive performance when stressed and when calmer. *Cereb. Cortex* 31, 1411–1426. doi: 10.1093/cercor/bhaa276

Zhang, H., Li, Q., Graham, R. K., Slow, E., Hayden, M. R., and Bezprozvanny, I. (2008). Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. *Neurobiol. Dis.* 31, 80–88. doi: 10.1016/j.nbd.2008.03.010

Zhang, P., Zheng, C.-B., Chen, Z., and Liu, X.-Y. (2023). Editorial: the role of calcium channels in human health and disease-volume II. *Front. Mol. Biosci.* 10:1180456. doi: 10.3389/fmolb.2023.1180456

Zhang, H., Zhu, S., Zhu, Y., Chen, J., Zhang, G., and Chang, H. (2011). An association study between SNAP-25 gene and attention-deficit hyperactivity disorder. *Eur. J. Paediatr. Neurol.* 15, 48–52. doi: 10.1016/j.ejpn.2010.06.001